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ABSTRACT 
The HIV-1 pandemic affects millions of people worldwide with approximately 70% of 
those affected residing in sub-Saharan Africa (SSA) relying on traditional medicines 
for treatment. The key aim of the study was to isolate and characterise an active 
phyto-pharmaceutical ingredient (API) from L. trigonus for use as a vaginal 
microbicide. 
The aerial parts of L. trigonus were oven-dried at 80°C, ground and then extracted 
with boiling water for 30 minutes. Aqueous extracts were screened using an HIV-1 
neutralization assay in TZM bl cells. Chromatographic and spectroscopic techniques 
were used to purify, isolate and identify the API. 
The API (BP36-117-26464C) was identified as a polymeric macromolecule with IC50 
= 0.04 µg/ml against HIV-1 HXB 2 subtype B. This activity is comparable to the ARV 
drug, enfuvirtide (IC50 = 0.02 µg/ml). The API consists of galacturonic acid polymer 
and a mixture of seven compounds. Its mode of action may involve inhibiting virus 
attachment. 
The activity of this precipitate (BP36-117-26464C) tested against HIV-1 subtype C 
pseudovirions and shown to compare favorably with that of enfuvirtide (T20). The 
water-soluble nature of this API and its mode of action identified it as a potential 
microbicide. In the current form, the precipitate (API) would be difficult to develop as 
an oral treatment for HIV, as high-molecular weight agents often have poor 
bioavailability following oral administration. However, large molecules with potent 
anti-HIV activity are ideal for topical use and potent development as a microbicide. 
KEY TERMS 
Lobostemon trigonus, traditional uses, anti-HIV, vaginal microbicide, formulations, 
HIV-1 neutralisation assay, phytochemistry, nuclear magnetic resonance 
spectroscopy, bornesitol, rosmarinic acid. 
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CHAPTER 1: INTRODUCTION 
1.HIV/AIDS and anti-HIV agents from plants 
1.1 HIV/AIDS: The Global Status 
Human immunodeficiency virus (HIV) is the pathogen that causes Acquired Immune 
Deficiency Syndrome (AIDS), a complex array of disorders resulting from the 
weakening of the immune system. Infected individuals become vulnerable to 
opportunistic pathogens such as common microbes and often suffer from 
tuberculosis (TB), pneumonia and rare forms of cancer (Tshikalange 2008) . HIV 
uses macrophages and T-cells as target cells to produce multiple progeny virions 
ready to infect new viral hosts. During each round of infection more cells of the 
immune system are damaged or killed. The host produces antibodies and helper T-
cells in order to fight the virus but eventually the virus prevails and opportunistic 
diseases associated with AIDS appear (Tshikalange 2008). 
By 2011, 34 million people were infected with HIV. These included an estimated 
0.8% of adults aged 15-49 years. The burden of the epidemic varies considerably 
between countries and regions and sub-Saharan Africa (SSA) remains most 
severely affected, with nearly 1 in every 20 adults (4.9%) living with HIV. This region 
accounts for 69% of the people living with HIV worldwide and shows an infection 
prevalence 25 times greater than in Asia (UNAIDS 2012). 
 
1.1.1 Causes of high rate of HIV infection in South Africa 
In South Africa, HIV is transmitted predominantly between heterosexual couples, 
with mother-to-child transmission being the other main infection route. Drivers of the 
epidemic in South Africa are intergenerational sex, multiple concurrent partners, low 
condom use, excessive use of alcohol and low rate of male circumcision. In relation 
to intergenerational sex, research has identified younger females having sex with 
older males as an important factor contributing to the spread of HIV. It has been 
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noted that such relationships are usually motivated by subsistence needs as well as 
being linked to materialism (Garcia-calleja & Barrerre 2010). 
Shisana and colleagues found a higher HIV prevalence among teenage males and 
females who reported having sexual partners who are five or more years older than 
themselves. Owing to unequal power dynamics in such relationships, vulnerability 
may be exacerbated for young girls who do not have the skills and power to 
negotiate condom use (Global AIDS response progress report 2012). 
 
1.1.2 The Need for Female Controlled Methods 
Biologically, women are 2-4 times more likely than men to be infected with HIV 
resulting from unprotected sex. Likewise, from an economics viewpoint, women tend 
to show an economic need or dependency on men and are less able to assert their 
rights. This is reflected in social and cultural societal features reflecting gender 
norms about sexuality and gender-based violence. In essence, current methods of 
sexual and birth control (abstinence, fidelity, and condom use) often requires male 
consent, participation and cooperation (Wanyoike 2011). 
The rapid increase of HIV infection among women in the world has been attributed 
primarily to sexual contact with HIV‐infected men. While a range of contraceptives 
protect against unintended pregnancies, only condoms, for both males and females, 
provide dual protection by stopping HIV transmission and preventing unintended 
pregnancies. The lack of methods of HIV prevention that are controlled by women 
and girls, along with low levels of condom use, place women and girls at increased 
vulnerability to HIV infection (UNAIDS & WHO 2012). 
Women need safe contraceptive and HIV prevention options that they can own and 
manage. New investments into research for female-controlled technologies that 
allow women to prevent both HIV and pregnancy are still essential. 
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1.2 HIV prevention Strategy: Microbicides as an alternative prevention method 
for women in the fight against HIV/AIDS 
Although a variety of inhibitors that target different steps in HIV-1 entry have been 
developed, only maraviroc, a small-molecule CCR5 antagonist, and enfuvirtide, an 
oligo-peptide fusion inhibitor, are approved for clinical use. Several other drugs are 
currently active in the development pipeline, and entry inhibitors may play an 
important role in preventing acquisition of HIV-1 infection (Henrich & Kuritzkes 2013). 
 
1.2.1 What are microbicides? 
Microbicides are compounds that can be applied inside the vagina or rectum to 
protect against sexually transmitted infections (STIs), including HIV. They can be 
formulated as gels, creams, rings, or suppositories (see Fig 1). Microbicides may or 
may not have spermicidal activity. 
To be truly female controlled, the ideal microbicide should be effective, safe, 
acceptable, affordable, colourless, odourless, stable, easy to store and use, 
available in formulations without any prescription. Microbicides offer many potential 
advantages for increasing a woman’s control over her sexual life and for protecting 
women, men, and children from infection (Attawell 2001). 
 
 
 
Figure 1: An example of a vaginal microbicide 
(http://www.natap.org/2012/CROI/croi_160.htm) 
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1.2.2 How does a microbicide work? 
Various STD’s including HIV pathogens can attack the body in multiple ways and an 
effective microbicide will help prevent infection by stopping this attack at one or more 
stages in the process (see Fig 2). The microbicides currently under development act 
in one or more of the following ways: 
o Killing or inactivating pathogens. Some microbicides work by breaking down 
the surface or envelope of the virus or pathogen. 
o Creating physical barriers. Microbicides could provide a physical barrier 
between pathogens and vulnerable cells in the epithelium (cell wall) of the 
vagina or rectum (Attawell 2001). 
o Strengthening the body’s normal defenses. The body has several naturally 
occurring defense mechanisms that a microbicide may be able to supplement 
or enhance. Lactobacilli, for example, are naturally occurring, “good” bacteria 
that helps protect the vagina by maintaining its acidic environment. This 
natural acidity helps foster an inhospitable environment for many pathogens, 
including HIV. Thus, the idea of developing a microbicide that supports the 
lactobacilli in performing this function is one potential mechanism of action 
being explored (Attawell 2001). 
o Inhibiting viral entry. Some microbicides bind to viruses and bacteria to 
prevent them from binding to and infecting healthy cells. 
o Inhibiting viral replication. Some candidate microbicides are being developed 
from the antiretroviral drugs that HIV-positive people use to lower the amount 
of virus in their bodies. Formulated as gels or creams, these drugs may be 
able to suppress replication of any HIV that enters the vagina or rectum during 
sex. If so, they could substantially lower the odds that the microbicide user will 
become infected or re-infected, if already HIV positive (Attawell 2001). 
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Figure 2: Various potential modes of microbicide action that may be effective against 
viral infection (Shattock & Rosenberg 2012) 
 
1.2.3 Challenges in developing a microbicide 
Ideally, a microbicide should not irritate tissue, it should quickly spread - this is 
especially important with tissue vulnerable to HIV infection - and it should remain in 
situ while walking and prior to sexual intercourse. A microbicide should be able to 
cross protective barriers such as membranes of the vagina or rectum and penetrate 
the surrounding tissue and nearby lymph nodes (Pebody 2011). 
Ideally, it should not enter the blood stream where its effect can be diluted and 
possibly lead to side effects. As an example of this, if an ARV-based microbicide was 
used by a person with undiagnosed HIV infection, the possibility exists that 
systemically distributed microbicide could lead to the development of drug-resistant 
HIV and limit future treatment options. An ideal ARV-based microbicide, then, should 
consist of a drug which is not already used for HIV treatment and with limited 
absorption into the bloodstream. 
This emphasises the advantage of a topical microbicide over oral pre-exposure 
prophylaxis. To increase compliant use, a feminine-oriented microbicide should be 
inexpensive, require no prescription, could be applied each day rather than when sex 
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is anticipated and could be dual-acting to simultaneously protect against pregnancy 
and HIV or single-acting to protect against HIV infection (Pebody 2011). 
 
1.2.4 Vaginal Microbicide studies 
In July 2010, the results of the CAPRISA 004 study were released. This blinded 
South African trial involved 889 sexually active women who were randomly selected 
to receive a microbicide gel containing 1% tenofovir (a nucleotide reverse 
transcriptase inhibitor) or a gel containing a placebo. The participants were at high 
risk of HIV infection, as indicated by the 9.1% annual incidence in HIV infection 
within the placebo group, while women in the test group showed a lower annual 
incidence of 5.6%. In other words, the study group showed a reduction of HIV 
incidence of 39% when compared to the placebo group. 
Results were shown to be better in women who used the microbicide consistently. 
The study showed that women who used the microbicide on at least 80% of the days 
they had sex showed a risk of infection that was 54% lower than the placebo group. 
However, the fact that overall compliance was poor highlights the possibility that 
consistent microbicide use may be as challenging as consistent condom use (Karim 
et al; 2010). 
Other South African studies include the, Vaginal and Oral Interventions to Control 
the Epidemic (VOICE) study which compared HIV infection rates in women using a 
tenofovir microbicide against a placebo  and an efficacy trial, IPM 009 that will test 
the effectiveness of dapivirine (a non-nucleoside reverse transcriptase inhibitor), 
either as a gel or as a vaginal ring. In addition, other preliminary studies (for 
example, in animals or to test safety in humans) are underway. At least 13 different 
ARV-based microbicide studies involving primates demonstrated efficacy in blocking 
HIV infection. Some of these ARVs are also used for HIV treatment, while others 
such as dapivirine show anti-HIV activity but are not licensed for HIV treatment 
(Pebody 2011). 
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1.3 HIV treatment 
Inhibiting the replication cycle stages has become an important part of treating and 
controlling HIV, although to date more inhibitors are still to be developed. Treating 
people with infected with HIV lowers the number of virions in their body and can 
dramatically reduce their risk of transmitting HIV to others, underscoring the 
importance of HIV testing and access to medical care and treatment (Centers for 
disease control and prevention (CDC) 2013). In fact, a landmark clinical trial in 2011 
showed that people infected with HIV who began taking anti-HIV medications early, 
before their immune systems were significantly weakened, experienced a 96% 
reduction in their risk of transmitting HIV to their sexual partners (Centers for disease 
control and prevention (CDC) 2013). 
Antiretroviral therapies have brought renewed hope for many people living with HIV. 
However, they do not offer a cure, and they can cause many side effects. HIV is 
treated with antiretrovirals (ARVs), which work against the HIV infection by slowing 
down the spread of the virus in the body (WHO et al; 2013). Patients tend to take 
three or more types of ARV medication. This is known as combination therapy or 
antiretroviral therapy (ART). Combining ARVs actually helps to reduce drug 
resistance as HIV can quickly adapt and become resistant to a single ARV. This 
means that the most common treatment for people just diagnosed with HIV involve 
taking just one or two pills a day. Different combinations of ARVs work for different 
people so the medicine they take is individual to them (WHO, UNICEF 2013). 
Recent studies confirm that gains in life expectancy among people living with HIV 
receiving ART in low and middle-income countries are as remarkable as those 
previously documented in the high-income countries of Europe and North America. 
In South Africa, for example, data from six HIV treatment programmes in three 
provinces show that adults starting ART have a life expectancy of about 80% of 
normal if they start treatment before their CD4 count drops below 200 cells/mm3ml 
(WHO, UNICEF 2013). 
Researchers from Beth Israel Deaconess Medical Centre; 2013 have identified a 
potentially powerful new treatment for HIV infection that makes use of recently 
discovered antibodies to disable the virus, a finding that promises to energize 
research in both prevention and treatment. It was found that administering a round of 
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potent human antibodies to monkeys infected with a hybrid version of HIV caused 
the amount of virus in their bodies to reduce to low or undetectable levels that were 
sustained for weeks. The virus dropped to undetectable levels within three to seven 
days after an intravenous infusion of a single antibody in one of the studies (Beth 
Israel Deaconess Medical Center (BIDMC) 2013). However there is still a need for a 
search for a drug that will permanently eradicate this HIV virus. 
 
1.4 HIV drug resistance problem - the need for prevention rather than a cure 
Therapy designed to impact on HIV infection has come a long way. However, many 
challenges still remain such as drug resistance which is a widespread problem that 
limits the efficacy of antiretroviral treatment. As indicated above, for antiretroviral 
treatment to be effective in the long term, it has been found that combination therapy 
should be administered (Dambuza 2007). 
In more developed countries, most HIV-1-infected patients are surviving longer with 
an improved quality of life where the progression to AIDS has been reduced as a 
result of this combined antiretroviral therapy. The term highly active antiretroviral 
therapy (HAART) is used to describe a combination of three or more anti-HIV drugs 
which include either a protease inhibitor or a non-nucleoside analogue reverse 
transcriptase inhibitor and two nucleoside analogue reverse transcriptase inhibitors. 
This combination can lead to prolonged virus suppression and immunological 
reconstitution (Dambuza 2007). 
Despite the beneficial effects of HAART, there are serious side effects of social, 
economic and clinical importance. First of all, according to the research done by 
Dambuza (2007), most infected persons live in countries where treatment is not 
available or is unaffordable. Secondly, the efficacy of HAART has resulted in a 
relaxation of appropriate health measures that threaten an outbreak of epidemic 
infection, especially in western countries. 
Lastly, antiretroviral drugs have several side effects, with different incidences and 
severities, including myopathy, migraine, dementia, ataxia, stroke-like episodes, 
hypertrophic cardiomyopathy, gastrointestinal complaints, increased bilirubin serum 
levels, nephrolitiasis, perioral paresthesias, diabetes mellitus, hypoparathyroidism, 
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hypogonadism, infertility, dysphagia, nausea, vomiting, intestinal pseudo obstruction, 
anemia, pancytopenia, pancreatitis, depression, amongst others (Dambuza 2007). 
With speedy development into understanding the structure and function of HIV, it is 
important that the growing knowledge from laboratory research be quickly directed 
into not only developing more drugs which may stop the replication of HIV but also 
into microbicides which may prevent infection altogether.  
 
1.5 Traditional and herbal medicine - a source of anti-HIV agents 
Plants have not only provided mankind with food, clothing, flavours and fragrances, 
but have also served humanity to treat different ailments. Plants are always 
surrounded by an enormous number of potential enemies such as bacteria, viruses, 
fungi etc. By nature plants cannot avoid these enemies simply by moving away, they 
protect themselves through chemical defence systems (Lewu & Afolayan 2009). 
Therefore, it is reasonable to expect biologically active compounds to be produced 
by plants as a chemical defence measure against their enemies. The search for 
biological active agents from plants is part of a wider recurrence of scientific interest 
to produce new chemotherapeutics. Plants synthesize very complex molecules with 
specific stereochemistry and can show biological activity with novel modes of action 
(Tshikalange 2008). 
Many useful drugs have been developed from medicinal plants used in traditional 
medicine in the treatment of a variety of illnesses and their use as a therapeutic 
modality continues to be effective (Gilani & Atta-ur-Rahman 2005). Most of the 
clinical drugs that are currently in use were derived from plants and developed 
because of their use in traditional medicine. Asperin (antipyretic), atropine, digoxin, 
morphine (pain killer), quinine, respine (hypertension) and tubocurarine are a few 
examples of drugs, which were discovered through the study of ethnobotany 
(Magalhães et al; 2010). 
Traditionally, herbs and herbal products have been considered to be nontoxic and 
have been used by the general public and traditional medicinal practitioners 
worldwide to treat a range of illnesses (Barnes et al. 2007). However, there is 
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relatively little published scientific research about the safety and efficacy of these 
herbal treatments. It is, therefore, important that these medicines are properly 
researched so that the safe and effective ones can be identified and used, and the 
ones that can harm people are withdrawn (Barnes et al. 2007). 
The World Health Organisation (WHO) estimated that around 80% of the population 
in Africa uses traditional medicines. In sub-Saharan Africa there is one traditional 
healer for every 500 people, whereas there is only one medical doctor for every 40 
000 people. It has been estimated that 70% of the South African population consult 
traditional healers and that the entire industry is worth well over R250 million 
(Masupha et al; 2013) 
Many people use traditional medicines to treat the symptoms of HIV and AIDS, and 
lots of claims have been made that some of these medicines can even cure HIV 
disease. Without scientific validation and proper clinical evaluation, these claims are 
considered as false, as no treatments, including ARVs, have been shown to cure 
HIV and AIDS (Vermani & Garg 2002). 
Some herbal treatments may help by attacking the virus directly or by stimulating a 
person’s immune system which then attacks the infected cells. Other studies have 
shown that in Europe herbal treatments are considered to be the most popular 
complementary medicine used by HIV-infected individuals. A substantial amount of 
research has been done and a lot more is in progress to isolate the active leads from 
plants for prevention of transmission of HIV and treatment of AIDS. These active 
principles may act by different mechanisms, targeting critical steps within the 
replication cycle of HIV (Vermani & Garg 2002).  
Several plants have been screened for activity against STD’s on the basis of 
ethnopharmacological data and some of these screening programs have yielded 
potential leads. Since then, medicinal plants have been used for the treatment of 
STDs and AIDS with little scientific evidence in traditional systems of medicine. In 
the last century enormous efforts were made to select the plants, isolate the active 
principles and screen the crude extract/fractions/compounds for activity against 
various sexually transmitted pathogens, and to elucidate their mechanism of action 
(Vermani & Garg 2002). 
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Studies have revealed that because of structural diversity of the natural products, 
they provide a large reservoir of compounds for screening of anti-HIV agents. Many 
compounds with anti-HIV-1 activity have been isolated from natural products and 
shown to inhibit HIV at nearly all stages of the viral life cycle (Moshi 2005). These 
compounds include alkaloids, sulphated polysaccharides, polyphenolics, flavonoids, 
coumarines, phenolics, tannins, triterpenes, lectins, phloroglucinols, lactones, 
iridoids, depsidones, O-caffeoyl derivatives, lignans, ribosome inactivating proteins, 
saponins, xanthones, naphthodianthrones, photosensitisers, phosholipids, quinines 
and peptides (Moshi 2005). 
A local study also revealed that two South African plants, Lobostemon trigonus and 
Sutherlandia frutescens have inhibitory activity against HIV-1 reverse transcriptase 
activity. Specifically the aqueous extract of Lobostemon leaves inhibited HIV-1 RT 
with an IC50 value of 49 µg/ml (Harnett et al; 2004). 
 
1.6 Value of the study 
People often claim that their traditional medicinal plant remedies could improve the 
quality of life of an HIV/AIDS patient. However, the efficacy of these remedies or 
plants has generally not been proved (Tshikalange 2008). South Africa is a country 
with a rich source of unexploited phytochemicals and it has an under-established 
culture of traditional medicine that could provide support for many HIV/AIDS victims. 
These drugs need to be studied to confirm and verify if they are effective as anti-HIV 
agents. In addition to contributing towards this body of knowledge, this study focuses 
on part of the development of a microbicide based on a South African indigenous 
plant used to treat HIV patients.  
 
1.7 Aim of the current study 
This study is part of a multidisciplinary consortium initiative comprising of several 
research groups within the Council for Scientific and Industrial Research (CSIR) as 
well as the Drug and Formulation group at the University of the Witwatersrand (Wits), 
South Africa. The CSIR Biosciences division has on-going collaborations with 
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Traditional Healers (TH) and indigenous knowledge holders on the use of medicinal 
plants in South Africa. This has led to the identification of a number of plants used to 
treat HIV. 
One of these plants, Lobostemon trigonus, is being used by a private individual in 
the Eastern Cape to treat HIV-positive patients. The traditional use of the plant is as 
a tea prepared from the dried aerial parts of the plant. In support of these activities, 
previous studies by Harnett et al. (2004) and Dambuza (2007) showed that an 
aqueous extract of L. trigonus inhibits HIV-1 reverse transcriptase. These authors 
used a range of solvents to extract most of the potential active compounds present in 
this plant species. 
The key aim of the current study is to isolate and characterise the most suitable API 
from Lobostemon trigonus, which will contribute to the overall development of a 
vaginal microbicide, ultimately leading to the empowerment of women to protect 
themselves from sexual transmission of HIV. 
 
1.8 Objectives of the study 
Infection with HIV continues to pose an extraordinary public health problem and 
current treatment options have not been satisfactory. The quest for effective curative 
or preventive therapies continues with plants increasingly seen as an alternative 
source for discovery of novel anti-HIV molecules. The objectives of the study are as 
follows: 
 To perform plant extractions and optimise the aqueous extraction method 
 To concentrate extracts using an ethanol precipitation method 
 To optimise the ethanol precipitation method 
 To biologically evaluate the different potential APIs 
 To purify the API using chromatographic techniques such as column 
chromatography (CC), thin layer chromatography (TLC) and vacuum liquid 
chromatography (VLC) and semi preparative high performance liquid 
chromatography (HPLC) as guided by the tested biological efficacy of each 
extract 
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 To characterise the potential API using specialized analytical techniques 
including nuclear magnetic resonance (NMR) and ultra-performance liquid 
chromatography- mass spectrometer (UPLC-MS) and gas chromatography 
(GC)  
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CHAPTER 2: PRELIMINARY DATA COLLECTION 
2. Primary identification stages of the potential API 
2.1 Lobostemon trigonus: Literature review 
Lobostemon belongs to the family of Boraginaceae and is mainly distributed in the 
Eastern and Western Cape regions of South Africa. A photograph of this plant is 
shown in Figure 3 below. Research on this plant has been limited to botanical 
studies to help characterise and classify the species and sub-species. According to 
the Angiosperm Phylogeny Group (APG III 2009) classification, Boraginaceae, the 
borage, or forget-me-not family, includes shrubs, trees, and herbs, totalling about 
2750 species in about 150 genera worldwide.  
The family is especially well represented in the Mediterranean region, but is also 
found in most temperate to subtropical areas. Lobostemon Lehmann (1830: 378), 
with 28 species, is the largest southern African genus in the Boraginaceae (Buys 
2011). This genus is mainly confined to the winter-rainfall area of South Africa, 
occurring from Springbok to Mossel Bay and further eastward along the coast to 
around Grahamstown, where rain may occur throughout the year (Buys 2011). 
Agtdaegeneesbos (eight day healing bush), Douwurmbos (dew worm bush), Luibos 
(lazy bush) and Geneesbos (healing bush) are the most common vernacular names 
for Lobostemon and these names are known to most rural folk in the Western 
Province of South Africa, and to those interested in South African medical plants in 
particular. 
One Lobostemon species, L. fruticosus, has been studied with regards to its 
medicinal properties particularly as L. trigonus, the species investigated in the 
present study, is not easy to cultivate nor to find in the wild. Furthermore, several 
studies have shown significant anti-HIV activity, specifically in vitro reverse 
transcriptase inhibition (Harnett et al; 2004). However, there is still a need to further 
investigate this plant species. 
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Figure 3: Left – regional distribution of L. trigonus (Foden & Potter 2005) Right - 
Picture of Lobostemon trigonus (Dambuza 2007) 
 
2.1.1 Medicinal usage 
Lobostemon, according to its traditional name, has an apparent ability to heal a 
condition in eight days. Another name used is “douwurmbos”, as it is believed to 
treat ringworm. Decoctions are used to treat wounds, skin disease, ringworm and 
ulcers while infusions are used for general internal problems and to purify the blood. 
The remedies all require an infusion of the leaves or a paste is made by either 
pounding the leaves or chewing them, the slimy paste is then topically applied to the 
wound or affected area (Appidi et al; 2008) 
 
2.1.2 Chemical constituents  
Little is known of the chemistry of this species, nor of others in this South African 
endemic genus. Members of the family are a common source of pyrrolizidine 
alkaloids and an example of this is shown as compound 1 in figure 4. These 
alkaloids accumulate in the liver and are toxic, thus, the use of food or products 
containing them should best be avoided (Martena 2010). As described in the study 
done by Sharma et al., (2009), various chemical constituents have been isolated and 
characterized from Boraginaceous plant species. These included naphthoquinone 
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derivative (compound 2, fig 4), bornesitol (compound 3, fig 4), phenolic acids, 
tannins and the ureide allantoin - the latter compound being particularly abundant in 
the root of comfrey, (Symphytum officinale). 
L. trigonus also contains sulphated polysaccharides, which proved to be one of the 
classes of compounds responsible for the anti-HIV activity. They appear to be 
present, as aqueous infusions are very viscous and set to a gel if in sufficient 
concentration (Harnett et al; 2004). 
N
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Compound 1: Pyrrolizidine alkaloids 
O
O  
Compound 2: Naphthoquinone derivative 
O
CH3
 
Compound 3: A cylitol, bornesitol 
 
Figure 4: Classes of the chemical constituents found in the Lobostemon genus  
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2.1.3 Biological properties 
The Boraginaceae family has been shown to possess a high-molecular, water-
soluble compound that was also isolated from the roots of S. asperum and to 
represent a new class of natural polyethers (Barbakadze, et al. 2000). Some plants 
species of the Boraginaceae family are a source of naphthaquinones (compound 2), 
red pigments which possess antibacterial, antifungal, anti-inflammatory and wound 
healing properties (Sharma et al; 2009). 
 
2.2 Materials and Methods 
Preliminary studies performed at CSIR Biosciences had revealed that the aqueous 
extract of the Lobostemon trigonus possessed anti-HIV properties. This preliminary 
research invented the current study, which focused on investigating the plant further 
for its anti-HIV properties. The overall intention was to isolate the API for use in the 
development of a microbicide. 
The initial research stages were to produce an aqueous extract (spray dried (flow 
diagram 2) and freeze dried extract (flow diagram 1) and also to screen it against 
HIV-1 subtype B and/or C strains. The full details of the initial identification, 
purification and isolation stages of the API are described below. The detailed 
methodology is discussed in chapter 7. 
 
2.2.1 Plant collection 
Plant material was collected from the Port Elizabeth region in the Eastern Cape, 
South Africa. The aerial plant parts were harvested and transported to the CSIR in 
Pretoria, where it was dried, ground and stored for future use. The aerial plant parts 
were identified by the South African National Biodiversity Institute (SANBI Genspec 
number: 1492 44) 
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2.2.2 Determination of the anti-HIV activity 
2.2.2.1 HIV Neutralization assay  
This is the primary assay employed in the current study and is conducted as a 
routine assay within CSIR Biosciences. It uses molecularly cloned HIV-1 
pseudovirions for greater reproducibility due to reagent stability. Envelope (env)-
expressing plasmids are co-transfected with backbone plasmid into 293T cells to 
generate pseudo viral particles. These pseudovirions can infect cells but are unable 
to reproduce due to the lack of the complete genome resulting in single-round 
infection (Montefiori 2008). 
 
These single-round infections are detected in genetically engineered cell lines that 
contain a Tat-responsive gene such as luciferase. TZM-bl cells (HeLa cell clones), 
engineered to express CD4, CCR5 and endogenous CXCR4 contain integrated 
genes for firefly luciferase and E.coli ß-galactosidase under control of an HIV long 
terminal repeat sequence. Once the virus infects the cell the viral Tat proteins 
induces the expression of the luciferase reporter gene, the activity of this gene is 
detected and quantified by luminescence and is proportional to the infectious viral 
particles that have entered the cell (Montefiori D. C 2008). Detailed protocols of this 
assay are found in chapter 7. 
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2.2.3 Preparation of the L. trigonus freeze-dried (aqueous) extract 
 
 
 
 
 
 
 
 
 
 
Flow diagram 1: Preparation of the freeze-dried extract and its efficacy against HIV-
1HXB2 pseudovirus. 
 
2.2.4 Preparation of the spray dried (aqueous) extraction 
The extraction method that was developed led to a spray-dried extract of the plant 
which was also shown to have in vitro efficacy against laboratory-adapted HIV strain 
isolates (IC50 = 1.5 µg/ml). This was done to increase the scale of production and to 
examine the effect of extraction method on efficacy. The same procedure, ratio of 
plant material and water was followed as the above (flow diagram 1). 
 
 
 
 
100 g of aerial plant parts 
Hot plant extract 
Add 1L of dH2O, boil for 30 min 
Freeze dry the frozen plant extract 
Cool at 4⁰C for 1 hr, filter by hydraulic press 
filter & filter paper then freeze at -20⁰C 
Freeze dried plant extract (6 g yield) 
Bioassay for the freeze dried extract (aqueous extract) 
Efficacy: IC50 against HIV-1HXB2 strain pseudo virus = 1.05 (µg/ml) 
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Flow diagram 2 : Production of spray-dried powder (aqueous) extract that provided 
sufficient material for bioassay-guided fractionation. 
 
2.2.5 Bioassay-guided fractionation of the L. trigonus aqueous extract 
Bioassay-guided fractionation based on in vitro activity against HIV-1HXB2 
pseudovirions was conducted on the aqueous extract of L. trigonus. Flow diagram 3 
below outlines the stepwise fractionation of the spray-dried extract (aqueous 
extract), later labelled as Lob-1-13A. All the extracts, fractions or compounds that 
showed activity are shaded in dark grey on the tables and on flow diagrams 
presented in this study. 
 
 
Aerial plant parts 
Add water & boil 
Plant + water 
Filter & concentrate the extract 
Spray dries the extract 
Spray dried extract (IC50 
= 1.5 µg/ml 
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Flow diagram 3: Flow diagram of the bioassay-guided fractionation of Lob-1-13A 
(spray dried extract) 
 
Bioassay 
>100 µg/ml Fraction 3 & 12 showed anti 
HIV activity 
Fraction 4, 5&6 showed 
anti HIV activity 
Bioassay Bioassay 
(20 g/500 ml) Spray dried extract (IC 50 =1.5 – 5 µg/ml) 
1.5L of EtOH (96%) 
Precipitate 
Recover the precipitate by centrifugation  
Wet precipitate Filtrate  
Centrifuge 
Precipitate wash (70% 
EtOH/dH2O) 
Separate the precipitate 
Precipitate BP36-117-26464C 
Combine filtrates 
Remove EtOH/ H2O by 
rotary evaporation 
Dried filtrate BP36-117-26454-B 
Bioassay (IC 50 = 0.04 
Bioassay (IC 50 =20 µg/ml) 
Purification of BP36-117-26464C 
Sephadex G25 Cellex-d cellulose Column chromatography- silica gel               HPLC-ELSD 
Chromatographic techniques& analytical method development 
Collected 15 fractions Collected 6 fractions Discontinued Collected 9 fractions 
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As the aqueous extract showed moderate activity (IC50 = 1.5 – 5 µg/ml) against HIV-
1 (HXB2 strain), it was then subjected to a liquid-liquid partitioning process, which 
was referred to as ethanol precipitation, in an attempt to purify and separate the 
chemical components that appeared to be responsible for the activity in this plant. 
The spray dried extract (20 g) was dissolved in distilled water (500 ml) to which was 
added 96% ethanol (1.5 L). The same method as described by Dambuza (2007) was 
used to remove the sulphated polysaccharides. 
 
2.2.6 Details of a bioassay-guided fractionation 
2.2.6.1 Silica gel column chromatography of the extract 
Column chromatography is suitable for the physical separation of gram quantities of 
material. A solvent acts as the mobile phase while a finely divided solid surface acts 
as the stationary phase. The stationary phase will adsorb the components of the 
mixture to varying degrees. As the solution containing the mixture passes over the 
adsorbent, the components are distributed between the solvent and adsorbent 
surface. This process may be described by three-way equilibrium between the 
sample, the solvent and the adsorbent (Walker 2006). 
Both the precipitate (BP36-117-26464C) and the aqueous extract (Lob -1-13A) were 
purified by silica gel column chromatography. Unfortunately, the separation was not 
successful as both samples were only soluble in water and it is not recommended to 
elute very polar components using water/MeoH on a column. In addition, it was not 
possible to purify the fractions on a silica gel column as it was time-consuming due 
to the extremely slow flow rate of the mobile phase. Chapter 7 has more details in 
this respect. 
 
2.2.6.2 Size exclusion chromatography (SEC) using Sephadex G25 
Size exclusion is a chromatographic technique in which molecules in solution are 
separated by their size, not by molecular weight. SEC is a widely used technique for 
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the purification and analysis of synthetic and biological polymers, such as proteins, 
polysaccharides and nucleic acids (Walker 2006). 
Sephadex is available in different particle size grades. The different grades give 
chromatographic beads with different efficiencies and operating pressures. 
Sephadex G-25 type (20-50 µm bead size and 100-5000 molecular weight range) is 
recommended for separations of biomolecules such as peptides and other small 
biomolecules. As compounds migrate with the solvent through the gel, small 
molecules become included into the gel matrix, whereas larger ones are excluded 
and migrate at a greater rate (Walker 2006). 
From the fractionation of the precipitate using Sephadex G 25, 15 fractions were 
generated and only fraction 3 (BP36-117-26486-III) and fraction 12 (BP36-117-
26486-XII) showed significant activity. This is shown in Table 3. After it showed 
consistent anti-HIV activity, the precipitate BP36-117-26464C was then used as the 
reference sample extract in all the bioassays performed in the present study. All the 
fractions generated from the columns were then tested in comparison with this 
precipitate. 
 
2.2.6.3 Ion exchange chromatography (IEC) using DEAE Cellulose (Cellex d) 
Ion exchange column chromatography is a process that allows the separation of ions 
and polar molecules based on their charge (Walker 2006).This technique is limited to 
mixtures that contain components carrying a charge. In this form of chromatography, 
the sorbent is usually a polymeric resin like cellulose (cellex d), which contains 
charged groups and mobile counter ions that may exchange with ions of a 
component as the mobile phase migrates through the sorbent. Separation is 
achieved by differences in the affinity between ionic components and the stationary 
phase. DEAE cellulose (Cellex-d) is used as the resin. It allows fast flow rates 
especially after fines removal, suitable for negatively charged biopolymers 
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2.3 Results and Discussion 
2.3.1 DEAE cellulose (Cellex-D) anion exchange column chromatography 
This was employed to purify only the precipitate BP36-117-26464C as the precipitate 
was considered to be the component that was most active against HIV-1 HXB2 
strain (0.04 µg /ml) and it was easy to dissolve compared to the spray dried extract. 
Six fractions were collected from the DEAE Cellex-d cellulose column. As the 
purification and separation progressed, a synergy effect was observed, which means 
the components were observed to lose activity as they were separated from each 
other. 
The fractions (F1, F2, and F3) did not show any significant activity, but fractions F4, 
F5, F6 showed some activity (see Table 1). When F1, F2 & F3 were combined, they 
showed no activity (IC50 value was >100 µg/ml) while a combination of fractions F4, 
F5 & F6 showed moderate activity. However, when F1, F2, F3, F4, F5 & F6 were 
combined, an increase in activity was noted (Table 2). 
Another approach to further prove the synergy of the DEAE Cellex-d fractions was to 
combine the six fractions with pre-isolated compound from L. trigonus called 
bornesitol. Chapter 4, section 4.2.5 has the details as to how the compound was re-
isolated. This compound is a myo-inositol methyl derivative found in several plant 
species. It was isolated as a pure compound (see fig. 14) from the aqueous extract 
of L. trigonus. When it was screened for activity, it showed no significant activity but 
when mixed with F1, F2, F3, F4, F5 and F6, the activity greatly improved (see Table 
2). This proved that the activity of the individual fractions, including the compound 
bornesitol, act synergistically.  
 
2.3.2 High Performance Liquid Chromatography - Evaporative Light Scattering 
Detection (HPLC-ELSD) 
High Performance Liquid Chromatography (HPLC) is a form of column 
chromatography used to separate, identify, and quantify compounds. In this study, 
HPLC coupled with an ELS detector was identified as another possible technique for 
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further purification and for the fingerprinting of the precipitate (BP36-117-26464C) 
and spray-dried extract (Lob-1-13A) which were referred to as the potential Active 
Phyto-pharmaceutical Ingredients (API’s). The problem with the method used was 
that the separation was done on a size exclusion column and the API size 
distribution appears to have spanned beyond the separation limit of the column.  
Because of the nature of the chemical components in the sample, API, the 
successful separation and identification of these compounds in the API required a 
specific column and a detector suitable for these compounds. Therefore, it was 
difficult to develop a method that can separate these components and also difficult to 
identify how many compounds were in the mixture. 
The ELSD did produce some results (see chromatogram 1) it is just that the API 
appears to have a very large molecular weight range. It was decided then to just 
collect a relatively few fractions (fraction A, B, C, D, E, F, G, H & I). These fractions 
were available based on the peak method which was employed to confirm their 
activity against HIV-1. All the peaks between 8 min – 14 min were collected as noted 
in chromatogram 1 below. However, when tested against HIV-1 HXB2, they showed 
an IC50 value of >100 µg/ml which was equated as no activity (see Table 1). This 
further proved that all the possible active compounds were possibly retained in the 
column which indicated that a better column was needed. Note that peaks around 20 
min consisted of solvent peaks. 
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Chromatogram 1: HPLC-ELSD profile of the BP36-117-26464C – Precipitate (API) 
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Table 1: Efficacy of the aqueous extract, precipitate, two internal standards, 
sephadex G 25 fractions and DEAE cellex-d cellulose fractions: IC50 against HIV-1 
HXB2 strain pseudovirus 
Sample name Sample 
description 
IC50 
(g/ml) 
HIV-1 
strain 
Method 
Lob-1-13A Aqueous extract 1.500 HXB2 Extraction 
BP36-117-
26464C 
Precipitate 0.040 HXB2 EtOH 
precipitation 
BP36-117-
26454B 
Filtrate 0.900 HXB2 Precipitate 
wash 
BP36-117-
26488-F1 
Cellex-d fraction >100 HXB2 Cellex-d 
column 
BP36-117-
26488-F2 
Cellex-d fraction >100 HXB2 Cellex-d 
column 
BP36-117-
26488-F3 
Cellex-d fraction >100 HXB2 Cellex-d 
column 
BP36-117-
26488-F4 
Cellex-d fraction  6.000 HXB2 Cellex-d 
column 
BP36-117-
26488-F5 
Cellex-d fraction 18.00 HXB2 Cellex-d 
column 
BP36-117-
26488-F6 
Cellex-d fraction 21.00 HXB2 Cellex-d 
column 
BP36-117-
26486-III 
Sephadex 
fraction3  
14.03 HXB2 Sephadex 
G25 column 
BP36-117-
26486-XII 
Sephadex 
fraction12 
27.04 HXB2 Sephadex 
G25 column 
BP36-117-
26474-A,B,C,D 
HPLC-ELSD 4 
fractions 
>100 HXB2 HPLC-
ELSD 
Enfuvirtide 
(T20) 
Internal 
standard 
0.020 HXB2 External 
sourced 
Tenofovir (TFV) Internal 
standard 
0.400 HXB2 External 
sourced 
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Note that Tenofovir is the reverse transcriptase inhibitor and Enfuvirtide is the fusion 
inhibitor. 
 
Table 2: Efficacy of the Cellex-d Cellulose fractions and their synergistic effect 
Sample 
name 
Source Combined 
fraction 
HIV 
Strain 
IC50 
(g/ml) 
BP36-117-
26504-C 
(Bornesitol) 
Aqueous extract Pure compound HXB2 >100 
BP36-117-
26504-C 
(Bornesitol) 
Aqueous extract F1,F2,F3,F4,F5
& F6 
HXB2 6.1 
BP36-117-
26488-F1-F3 
Cellex-d cellulose 
column 
F1, F2 & F3 HXB2 >100 
BP36-117-
26488-F4-F6 
Cellex-d cellulose 
column 
F4, F5,F6 HXB2 24.0 
BP36-117-
26488-F1-F6 
Cellex-d cellulose 
column 
F1,F2,F3,F4,F5 
& F6 
HXB2 12.0 
BP36-117-
26464C 
Precipitate  Reference 
sample 
HXB2 0.04 
 
 
2.3.3 Ethanol precipitation of the aqueous extract 
Many compounds from this class (sulphated polysaccharides) have already been 
described extensively in the literature as having anti-HIV activity (Harnett et al, 2004; 
Dambuza 2007). This research also involved the removal of tannins and sulphated 
polysaccharides to further prove that potential anti-HIV activity seen in the aqueous 
extract of L. trigonus was not due to these class of compounds, indicating that there 
is another group or class of compounds responsible for the activity in this plant. 
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The filtrate named as BP36-117-26454B which in this present study is referred to as 
the precipitate wash, was dried and HIV-screened. Improved anti-HIV activity was 
observed for the precipitate (see flow diagram 3 above) – BP36-117-26464C (IC50 
0.04 g/ml) compared to the aqueous extract, Lob -1-13A, which showed moderate 
activity (IC501.5 - 5 g/ml). The activity of the precipitate against the HXB2 HIV-1 
strain compared favourably with that of T20 and Tenofovir (Table 1). 
 
2.3.4 Elementary Analysis of the precipitate (API) 
Elemental analysis on carbon, hydrogen and nitrogen is the most essential and, in 
many cases, the only investigation performed to characterize and/or prove the 
elemental composition of an organic and/or aqueous sample. This aspect of analysis 
was very important, as it was going to give an indication of what the API was roughly 
made up of. The API (BP36-117-26464C) was sent for the elementary analysis using 
the Leco Truspec CHN Analyser. The percentage composition of elements in the API 
is summarised in table 3 below. 
 
Table 3: Elementary composition of the API 
 
Sample name 
 
%C 
 
%H 
 
%N 
 
BP36-117-26464C 
 
41.8 
 
4.605 
 
1.1687 
 
 
The results above (table 3) showed that the API is made up of 47.5 percent of 
carbon (C), hydrogen (H) and nitrogen (N). It was speculated that the other 52.5% 
could be oxygen (O) and/or other elements. Unfortunately, these speculations could 
not be verified. They are still to be investigated. 
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2.3 Conclusions 
Both freeze dried and spray-dried aqueous extracts (Lob-1-13A) of the plant 
showed good anti-HIV activity (IC50 = 1-5 g/ml) against laboratory-adapted 
pseudovirus in the neutralisation essay, but the precipitate (BP36-117-26464C) was 
the most potent with an IC50 of 0.04 g/ml. Bioassay-guided fractionation of the 
aqueous spray-dried extract identified a polymeric molecule as the API showing 
anti-HIV activity in the same order of magnitude as Zidovudine (AZT), Enfuvirtide 
(T20), Tenofivir and Nevirapine (NVP).  
The aqueous solubility of this API indicated that it was more amenable to 
formulation as a topical microbicide for the prevention of sexual transmission of HIV 
in women. A target-based, time of addition assay showed that the API acts as an 
HIV attachment inhibitor, thus, substantiating its use as a topical microbicide (Van 
Den Berg et al; 2010). As such, the API extracted from the aerial parts of L. trigonus 
has enormous potential to block HIV infection and, in addition, to further counteract 
the development of drug resistance by HIV. In future, drug resistance could be a 
major problem, and in this regard, multiple and/or non-specific methods of action 
could be a solution to such a problem. 
In observing the physical properties of all the fractions obtained from Sephadex and 
Cellex-d cellulose columns, they were found to be brownish in colour, with a plastic 
and crystalline, sugar-like texture. In addition, they were all water soluble. All the 
physical properties of the fractions indicated that they were polymeric in nature or 
were molecules attached to sugars. 
Finally, it didn’t seem practical to continue purifying the individual fractions (from 
Sephadex G 25 and DEAE Cellex-d column) since they either lost or showed, at 
best, only moderate activity. Therefore, the partial characterization of the precipitate 
BP36-117-26464C (IC50 = 0.04 g/ml) was prioritized since it showed superior 
activity and consistently positive results.  
Elementary analysis for other suspected elements such as phosphorus (P), sulphur 
(S) or any other possible metals could not be determined. Only four elements were 
A         B              C          D 
31 
 
detected, (carbon, hydrogen, O and nitrogen) and those were expected since the 
API was an organic sample, and the lobostemon genus was reported to be rich in 
nitrogen containing compounds such as pyrrolizidine alkaloids. 
The main goal of characterization was to identify its structural components and 
perform fundamental analysis using nuclear magnetic resonance, gas 
chromatography and ultra- performance liquid chromatography mass spectrometry. 
This will be discussed further in chapter 4. 
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CHAPTER 3 : METHODS MODIFICATION 
3. Process development 
3.1 Process optimization 
Most processes, be it physical, chemical or otherwise, can be improved. While 
designing experiments, they require a deep understanding of influences that achieve 
desirable performance. The need for an efficient and systematic decision-making 
approach drives the need for optimization strategies. This chapter provides an 
overall description of how the aqueous extractions of L. trigonus and ethanol 
precipitation methods were optimized in order to identify the best API for further 
development as a microbicide. Several variables were investigated, such as: 
 Plant part (leaves, stems and combination of both) 
 Pre-processing of plant material (fresh or dry, milled or un-milled) 
 Extraction temperature (4°C and 95°C) 
 Dissolution volume of an extract (between 200 ml – 400 ml)  
 Precipitate wash composition (0%, 50% and 70% EtOH/H2O)  
 
At every stage of the process optimisation, the API yield and activity were assessed 
to identify the optimal variable. The HIV-1 pseudovirion neutralisation assay was 
used to evaluate activity. Note that all the extracts, fractions or compounds that 
showed activity are shaded in dark grey on the tables and flow diagrams. 
Values such as IC50 indicate the activity of extracts, fractions, compounds and 
precipitate and IC50 is defined as the concentration of an inhibitor required to give 
50% inhibition of an activity, where the smaller the value the greater the activity. 
Strain HXB2 is an HIV-1 strain used in the current study and compounds such as 
AZT (Reverse transcriptase inhibitor), Tenofivir (nucleotide reverse transcriptase 
inhibitor) and Enfuvirtide (fusion inhibitor) were the internal standards used. 
Optimisation experiments were conducted at laboratory scale. 
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3.1.1 Optimisation of the aqueous extraction method 
Optimization of the aqueous extraction method was carried out to investigate the 
effect on yield and activity by the following: 
 Freeze-drying as an alternative to spray drying of aqueous extract 
 Performing the aqueous extractions at 4°C and 95°C 
 Extraction of leaves and stems separately instead of in combination 
Several other potential variables could have been included, such as the microwave 
extraction, organic extraction instead of aqueous extraction, as they could have had 
an impact on the efficacy and yield, but because of the restricted time allocated for 
these experiments, it was impossible. So, only the primary variables were 
considered.  
 
3.1.1.1 Freeze-drying versus spray-drying 
Preparation of the spray-dried extract was time-consuming and energy-intensive. 
(Flow diagram 2). This consisted of several processes and the spray dried extract 
was difficult to dissolve as it showed a tendency to gel. However, preparation of the 
freeze-dried extract was practically efficient and proved easier to re-dissolve. In 
terms of the efficacy, there was no difference as both extracts were active to the 
same order of magnitude (flow diagram 4 for the IC50 values). The best method to 
dry the extract was decided to involve freeze drying as it was fast, potent and 
produced material that was more readily soluble and in higher yield.  
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Flow diagram 4: Effect of eliminating the spray drying process and introducing 
freeze drying process after aqueous extraction leading to increased anti-HIV activity 
 
3.1.1.2 Plant pre-processing and extraction temperature 
Another variable investigated was whether the activity was restricted to either the 
leaves or stems. A portion of fresh leaves and stems of L. trigonus was collected and 
extracted separately with cold water (4⁰C) and boiled water (95⁰C) to also validate 
the effect of temperature on anti-HIV activity. The extraction and the efficacy were 
assessed on each plant part at the two temperatures in comparison with dried 
ground aerial parts (i.e. combination of leaves and stems) see flow diagram 5 
below). 
 
 
 
Spray dried extract 
Plant material (leaves +stems) 
Milled plant material (100 g) 
Oven dried, ground aerial material 
Hot plant extract 
Add 1 L dH2O, boil for 30 min 
Cold filtered plant extract 
Cool at 4⁰C, 1 hr, Filter 
Freeze dried extract  
Freeze-dry extract 
Bioassay (IC50 = 1.50 g/ml) 
Yield = 10 g 
Plant material (leaves + stems) 
Ground plant material (100 g) 
Hot plant extract 
Cold filtered plant extract 
Spray-dry extract 
Yield = 7 g 
Bioassay (IC50 = 1.30 g/ml) 
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Flow diagram 5: Optimization of the production of the aqueous extraction: 
preparation of the aqueous extract at 95°C (unprocessed leaves vs. unprocessed 
stems vs. dried ground aerial parts). Abbreviations include UL (unprocessed leaves), 
US (unprocessed stems) and GM1 (Ground aerial parts).  
 
The results demonstrated that the fresh leaves (BP36-117-26487-UL) and stems 
(BP36-117-26487-US) extracts at 95°C did not exhibit activity (see flow diagram 5 
above) unless being processed by methods such as oven drying, crushing and 
milling. The same extraction process was repeated but with cold water at 4°C. No 
distinction was observed in terms of the efficacy on the cold water extracts of the 
leaves and stems as individual components. However, the dried ground aerial parts 
of the plant from which were extracted BP36-117-26487-GM1) (IC50 = 0.9 µg/ml) 
showed consistently good activity for both 4°C and 95°C. 
 
5 g unprocessed fresh Leaves 5 g unprocessed fresh Stems 5 g dried ground aerial parts 
Add 20ml H2O, boil 
Hot extract 
Hot extract Hot extract 
Stems extract (BP36-117-
26487-US) 
Leaves extract (BP36-117-
26487-UL) 
Aerial parts extract (BP36-117-
26487-GM1) 
>100µg/ml >100µg/ml 
IC 50 = 0.9 g/ml 
Filter, cool & dry 
Bioassay 
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3.1.1.3 Remarks on processed aerial plant parts 
The leaves and the stems were processed as the individual components (oven dried 
at 80°C and partially milled). They were extracted with hot water (95°C) and found to 
show significantly increased activity (see flow diagram 6 below). Thus, it is possible 
that oven drying (temperature) and grinding (physical processing) aid in the 
formation and/or the extraction of the anti-HIV constituents. The same extraction 
experiment was repeated but at a different temperature (4°C) and the anti-HIV 
activity was the same. 
 
 
 
 
 
 
 
 
 
 
 
Flow diagram 6: Optimization of the production of the aqueous extraction: 
preparation of the aqueous extract at 95°C (processed leaves vs. processed stems 
vs. dried ground aerial parts. 
 
It was then speculated that processing the plant material (i.e. addition of energy) aids 
in the release and extractability of the bioactive constituents, resulting in improved 
anti-HIV activity. This suggestion is supported by traditional healers who often use 
Bioassay 
5 g processed leaves 5 g processed stems 
5 g ground aerial plant 
material 
Add 20 ml dH2O, boil 
Hot extract Hot extract 
Hot extract 
Stem extract (BP36-117-
26487-PS) 
Leaves extract (BP36-
117-26487-PL) 
Ground aerial extract BP36-
117-26487-GM2) 
IC 50 = 2.8g/ml IC 50 = 2.7g/ml IC 50 = 0.9 g/ml 
Filter, cool it & dry 
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their hands or a hammer to partially process the plants before they prepare the 
decoctions for their patients. However the scientific explanation is that, oven drying 
would break the cell membranes and that ground material consists of smaller 
particles that will be extracted much more efficiently than large particles. The 
temperature in terms of boiling water (95°C) or cold (4°C) water during extraction 
had no effect whatsoever and it appears that the most important variable in 
producing an API was the plant processing (oven drying and grinding/milling ). 
 
3.1.2 Optimization of the ethanol precipitation method 
In order to optimise the ethanol precipitation method, two variables needed to be 
investigated: 
 The volume of water (200-400 ml) required to dissolve the spray dried extract 
for ethanol precipitation process  
 The solvent system (0%, 50% and 70% EtOH/H2O) required to wash the 
precipitate during the ethanol precipitation process 
Both variables were considered vital as they were observed to affect the efficacy and 
the yield of the API. 
 
3.1.2.1 Details of the dissolution volume 
The first variable to be optimised was the amount of water required to dissolve the 
spray dried extract. The main difficulty with the spray dried extract was that it was 
difficult to dissolve completely. In addition, this process was time consuming as this 
extract would gel and develop lumps. Determining the correct volume (200 ml - 400 
ml) of water was vital to optimally dissolving 10 g of the spray dried extract for the 
ethanol precipitation and ultimately to produce the API with the greatest activity. The 
process is shown in the flow diagram 7 below. 
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Flow diagram 7: Optimization of ethanol precipitation – investigating the volume of 
water to dissolve 10 g of the extract  
 
 
 
 
 
 
 
 
 
 
10 g of spray dried extract  10 g of spray dried extract  
 Dissolve in 350ml dH2O 
 Sonicate 
  Cool @ 4⁰C & add 1050ml 
EtOH 
10 g of spray dried extract  
 Dissolve in 300ml dH2O 
 Sonicate 
 Cool @4⁰C & add 900ml 
EtOH 
 Dissolve in 250ml dH2O 
 Sonicate 
 Cool @4⁰C &add 750ml 
EtOH 
Precipitate forms Precipitate forms Precipitate forms 
Wet precipitate 
Centrifuge, discard upper 
layer, wash precipitate (50%, 
50% EtOH/H2O) & centrifuge 
until colour is clear 
Centrifuge, discard upper 
layer, wash precipitate (50%, 
50% EtOH/H2O) & centrifuge 
until colour is clear 
Centrifuge, discard upper 
layer, wash precipitate (50%, 
50% EtOH/H2O) & centrifuge 
until colour is clear 
Wet precipitate Wet precipitate 
Evaporate EtOH, freeze 
dry & HIV screening 
Precipitate – BP36-117-
26463A (Yield = 2.4g) 
Precipitate – BP36-117-
26463B (yield =2.9 g) 
Precipitate – BP36-117-
26463C (yield =3.81 g) 
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Figure 5: Use of the anti-HIV assay to select the optimal volume of water required to 
dissolve 10 g of the extract for precipitation. 
 
Based on the efficacy and the yield, the amount of water selected to dissolve the 
spray dried extract was 250 ml (see flow diagram 7 and fig 5 above). This was 
expected as the lower the volume of water, the more concentrated would be the 
extract, the higher the yield leading to an increase in the anti-HIV activity. 
Remarks: To dissolve 10 g of the extract in 350 ml of distilled water took about 7 
hours, for 300 ml it took 8 hours and for 250 ml it took about 9 hours. As it was time 
consuming to perform these experiments, there was still then a need to investigate 
the best way or method of preparing a bigger batch of the precipitate (the API) or a 
bigger scale without having to waste time and resources. 
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3.1.2.2 Details of the Precipitate wash  
To form a precipitate, the dissolved aqueous extract (250 ml) was mixed with 750 ml 
(1:3 ratios) of 96% ethanol. The precipitate was then recovered through 
centrifugation. To wash the precipitate, a mixture of ethanol & water was used until 
the solution (wash) was clear. It was observed that during the washing of the 
precipitate, some of the bioactive compounds were lost due to solubility in the wash 
solvent (see yields on flow diagram 8). To avoid this, an investigation of the ideal 
wash solvent (0%, 50% and 70% ethanol/water ratios) was conducted. All the other 
variables previously discussed were kept constant during the optimization process. 
The detailed method is shown below on the flow diagram 8. 
 
 
 
 
 
 
 
 
 
 
 
Flow diagram 8: Optimization of ethanol precipitation involving between 0% - 70% 
EtOH/H2O solvent ratios to wash the precipitate and its resulting efficacy. Internal 
standards (T20 - IC50 = 0.02 µg/ml and AZT – IC50 = 0.4 µg/ml)  
 
 
10 g of spray dried extract  10 g of spray dried extract  
 Dissolve in 250 ml dH2O 
 Sonicate 
  Cool @ 4⁰C & add 750 ml EtOH 
10 g of spray dried extract  
 Dissolve in 250 ml dH2O 
 Sonicate 
 Cool @4⁰C & add 750 ml EtOH 
 Dissolve in 250 ml dH2O 
 Sonicate 
 Cool @4⁰C &add 750 ml EtOH 
Precipitate forms Precipitate forms Precipitate forms 
Wet Precipitate 
Centrifuge, discard upper layer, 
and wash precipitate (0% EtOH 
/H2O) & centrifuge until colour is 
clear 
Centrifuge, discard upper layer, 
wash precipitate (50%, EtOH /H2O) 
&centrifuge until colour is clear 
Centrifuge, discard upper layer, 
wash precipitate 
(70%EtOH/H2O) & centrifuge 
until colour is clear 
Wet Precipitate Wet Precipitate 
Evaporate EtOH, freeze dry & 
HIV screening 
Precipitate (1.5 g) –BP36-117-
26464A (IC50 = 0.07 µg/ml) 
Precipitate (3.2 g) – BP36-117-
26464B (IC50 = 0.06 µg/ml) 
Precipitate (5.4 g) – BP36-117-
26464C (IC50 = 0.04 µg/ml) 
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3.2 Conclusion 
Optimization of the aqueous extraction method showed that hot water extraction was 
the best method. This was in line with the traditional use of the medicinal plant. 
Fresh leaves and stems did not exhibit any activity, possibly because they were 
harvested, washed and then extracted and the active components could have been 
diluted to reduce their extractability and activity. Although partially processed leaves 
and stems individually produced significant activity, a combination of leaves and 
stems, which are fully processed (dried and ground), gave the best activity. The 
same ratio of water to plant material was used for scale up productions of the API. 
After the addition of 96% EtOH into the extract as showed in flow diagram 7, the 
precipitate formed immediately and the extract was then centrifuged to recover the 
precipitate that appeared as a jelly-like residue. The aqueous layer from the 
precipitation was decanted and was referred to as “filtrate” showed moderate activity 
(IC50 = 20.5 µg/ml), and the water soluble residual gel, which was referred to as the 
precipitate, was the most active (IC50 = 0.04 µg/ml). This activity compared 
favourably with virus fusion inhibitor Enfuvirtide (T20). 
From the flow diagram 8 shown above, the most active API selected was that of 
BP36-117-26464C with an IC50= 0.04 µg/ml. This was prepared from 10 g of extract 
in 250 ml, 70% EtOH/H2O for precipitate wash. This selected API (BP36-117-
26464C) was further purified and characterized as it was still a mixture of unknown 
active compounds. The purification and fractionation of the API is discussed in 
Chapter 4. 
The same parameters and protocols as described above were up-scaled and used to 
produce a large scale batch of the API (57 g) – see flow diagram 9 below. In terms of 
plant parts, oven dried, ground aerial parts appeared to be best when it comes to 
preparation of the precipitate and for future experiments including formulations. 
Please note below: the illustration of how the large batch of the API was prepared 
for the formulation and other necessary in vivo and in vitro assays including the 
PBMC’s assay. 
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Flow diagram 9: Illustration of the large-scale batch preparation of the API 
 
This batch (flow diagram 9) was produced for the development of the API into a 
microbicide, an API that will be formulated into gels and caplets. These formulations 
are identified as the most suitable formulations for women to use to protect 
themselves from sexual transmission of the HIV and other STI’s. More details 
concerning the formulations and development of the API as a microbicide is 
discussed in Chapter 5. 
100 g (repeated 10 times) of ground aerial plant parts 
Aqueous extract (750ml)  
Centrifugation 
Wet Precipitate (API) 
Add 1L dH2O, boil, filter, and 
cool @4°C for 30min 
Add 2,25L of 96%EtOH (1:3 ratio), 
precipitate forms, and cool @ 4°C for 
30min 
5000 x g, 15 min, @4°C and decant 
upper layer (EtOH/H2O filtrate) 
Precipitate (API) – 57 g 
Precipitate wash with (70% EtOH/H2O 
v/v) until clear, freeze dry the 
precipitate 
HIV screening  
Efficacy: IC50 against HIV-1HXB2 strain pseudo virus = 0.06 µg/ml 
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CHAPTER 4: PHYTOCHEMISTRY 
4. Isolation and Characterization of the API  
4.1 Isolation of the API  
4.1.1 Introduction 
Chapters 2 and 3 explained how the aqueous extractions and ethanol precipitation 
methods were modified and optimised, to ultimately produce the API BP36-117-
26464C. This chapter contains a summary of how the API was purified and 
characterised using different high-end techniques. 
At every stage of the purification process, the compounds and/or fractions were 
consistently assessed in terms of their bioactivity using the HIV-1 pseudovirion 
neutralisation assay. The IC50 values indicated the activity of the individual 
compounds and other activity-rich fractions and are shown in the flow diagrams and 
tables. In this assay, HXB2 is an HIV-1 strain used, AZT (reverse transcriptase 
inhibitor), Tenofivir (nucleotide reverse transcriptase inhibitor) and Enfuvirtide (fusion 
inhibitor) are the internal standards utilised. All the extracts, fractions or compounds 
that showed good activity (<20 µg/ml) are shaded in dark grey on the tables and flow 
diagrams, moderate activity (<50 µg/ml) is shown in light grey and lastly weak 
activity (>100 µg/ml) is represented by a very light, almost white grey colour. 
 
4.1.2 Purification of the API 
In this study, chromatographic techniques such as Liquid-liquid chromatography and 
thin layer chromatography (TLC) were used in order to purify the API. As described 
in chapter 2, the API could not be fractionated through a normal column or using 
High Pressure Liquid chromatography (HPLC - reverse phase) due to the polymeric 
nature of the API. The API was also discovered to consist of a high molecular weight 
compound/s that showed potent activity against HIV-1 pseudo virus (IC50 = 0.04 
µg/ml). 
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For the API to be purified, it had to be re-extracted with different polar solvents 
(liquid-liquid partitioning) to release all the possible soluble compounds in the API. 
The API was also treated with a polymer called polyvinylpolypyrrolidone (PVPP) in 
order to adsorb all the polyphenols in the API. All these efforts were aimed at 
discovering different classes of compounds present like fatty acids, sugars, alkaloids 
and polyphenols. To fractionate the API so that compounds can be easily separated 
and isolated, a selection of chromatographic techniques were attempted.  
 
4.1.2.1 The Use of the PVPP in the extraction of the polyphenols 
Polyvinlypolypyrrolidone (PVPP) is an organic solvent and water insoluble polymer. It 
is a light and creamy white powder. It is also insoluble in strong acid minerals and in 
alkali with stable foam being produced. It is very expensive but can be reusable. It  
absorbs water and swells very rapidly generating a swelling force. This compound 
forms bonds similar to peptide bonds in protein and that is why it can precipitate 
tannins the same way as proteins do. It is a highly cross-linked modification of 
polyvinylpyrrolidone (PVP) (Magalhães et al; 2010). 
 
 
 
Figure 6: Illustration of hydrogen bonding between the proton donor from the 
polyphenol and the carbonyl group from PVPP. 
 
As seen in Figure 6 above, it has been known for some time that phenolic 
compounds bind to polyvinylpolypyrrolidone (PVPP) (Magalhães et al; 2010). PVPP 
in the present study was used as a decolorizing agent (see chapter 5) and to adsorb 
the polyphenols which were thought to be partially responsible for the anti-HIV 
activity.  
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4.1.2.2 Detection of polyphenols such as flavonoids in the API 
Flavonoids are water soluble polyphenolic molecules containing 15 carbon atoms. 
They can be visualized as two benzene rings (see fig 7) which are joined together 
with a short three carbon chain. They also consist of 6 major subgroups: chalcone, 
flavone, flavonol, flavanone, anthocyanins and isoflavonoids. Together with 
carotenes, flavanoids are also responsible for the colouring of fruits, vegetables and 
herbs (Magalhães et al; 2010). 
With regards to detection, flavonoids normally produce yellow-brown spots on a 
white background when treated with iodine and ammonia vapour. Flavonoids may 
appear as dark spots on green background fluorescent when observed under UV 
light at 254 nm. Similarly under UV light at 366nm spot, colours depending on the 
structure of flavonoids can be yellow, green or blue fluorescent. It would be more 
clear and intense after being sprayed with the reagent. 
 
 
 
Figure 7: An example of a polyphenol compound 
 
4.1.2.3 Separation of polyphenols in the API by PVPP 
A liter (L) of the API was prepared as described in flow diagram 10 below, it was 
then mixed with 50 g of polymeric PVPP. The mixture was exhaustively mixed and 
stirred overnight for a complete adsorption of the polyphenols by the PVPP. The next 
day, the PVPP residue (pellet) and the filtrate (decolorized aqueous layer) were 
separated and recovered through centrifugation (5000 x g, 15min, at 4°C).  
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The PVPP residue and filtrate were freeze dried and weighed. The 
extraction/desorption of polyphenols was achieved by mixing 20 g of the PVPP 
residue with 400 ml of 70% Acetone/H2O. This mixture was thoroughly stirred 
overnight for complete extraction. Finally, a light brown extract containing the 
polyphenols and PVPP was separated by centrifugation. After filtration through a 
filter paper to remove the very small particles of the PVPP still in the mixture, the 
acetone-water extract was vacuum dried so as to remove the water and acetone as 
shown in Flow Diagram 10 below. The extract was subjected to the biological assay 
for the anti-HIV activity. The same extract was also phytochemically screened for the 
presence of polyphenols. 
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Flow diagram 10: Flow diagram illustrating the extraction and biological efficacy of 
the Acetone/H2O extract (containing the polyphenols) 
 
The polyphenol rich extract (Acetone-water extract) exhibited anti-HIV activity with 
an IC50 of 8 µg /ml. Also the TLC profile of the extract confirmed the presence of 
polyphenols as expected but the intensity of the spots was very weak even though 
these compounds were UV active. For the separation and purification of these 
compounds, semi-prep HPLC was employed  
 
Dark brown PVPP residue-52 g 
1 L (100 g / 1 L) of the Active Pharmaceutical Ingredient (IC 50 = 0.04µg/ml) 
Centrifuge 
Add 50 g of the PVPP, stir for 24 hours 
Discard upper layer 
Upper layer-liquid Bottom – PVPP pellet 
Less coloured API- 6g 
Freeze dry 
Freeze dry 
IC 50 value = 0.8-1.5 µg/ml) 
HIV screening 
20 g of PVPP-residue, add 400 ml of 
70% Acetone/H2O, 24 hr. stir 
Filtered by filter paper (x 4)  
Semi prep HPLC & TLC profile  
Concentrate the acetone/ H2O 
extract 
IC 50 value = 8 µg/ml) 
HIV screening 
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4.1.2.4 Semi prep HPLC-guided isolation of polyphenols in the API 
Preparative high-performance liquid chromatography (prep-HPLC) is a method 
needed to satisfy the purity specifications required on a routine basis, and it is also 
an important industrial separation process for the isolation and purification of 
pharmaceuticals and other valuable products. 
The precipitate (API) had initially been purified on a semi prep HPLC but no 
successfully separation was observed. Identifying the correct column was also a 
problem. Given this reason, it was then decided to determine the semi prep HPLC 
profile of the Acetone-H2O extract from a PVPP extraction (explained above in flow 
diagram 10). It was the only extract subjected to the semi prep HPLC as it showed a 
well resolved profile, had a better anti HIV activity (IC50 = 8 µg/ml) than other extracts 
(table 4). The Acetone-H2O extract showed four major peaks at 15-65 min retention 
time. Please see chromatogram 2 below.  
Several runs were conducted so as to develop a reproducible method that can 
actually separate the compounds in the acetone-H2O extract. Water and acetonitrile 
were the solvents used for the method development and optimization. A peak-based 
collection method was identified as the best collection method, and the best 
wavelength to detect the peaks was 320 nm. Please see chromatogram 2. 
Several fractions were collected from the semi preparative HPLC. The fractions were 
subjected to phytochemical analysis and HIV screening. TLC analysis (iodine and 
ammonia spraying reagents), mass spectrometry and NMR analysis were also 
conducted. The fractions that showed the highest levels of purity were then shown to 
be flavonoids. The dark spots that were visualized under the 254 nm UV lamp and 
appeared blue under long (366 nm) wavelength, tested positive after being exposed 
to an iodine and ammonia vapour which further confirmed the presence of 
flavonoids. 
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Chromatogram 2: Semi preparative HPLC profile of the acetone-H2O extract, at 
different wavelengths (254 nm, 280 nm, 360 nm and 320 nm). 
254 nm 
280 nm 
360 nm 
320 nm 
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4.1.2.5 Phytochemical detection of Alkaloids in the API 
Alkaloids are low molecular weight nitrogenous compounds and about 20% of plant 
species have been found to contain them. They are mainly involved in plant defense 
against herbivores and pathogens but can be utilized by humans (Roeder 1999). 
Plants containing these alkaloids have been used throughout history as poisons, but 
many of the alkaloids do have valuable pharmaceutical properties (Roeder 1999). 
The plant investigated in the present study is from the Boraginaceae family which is 
known to possess pyrrolizidine alkaloids. These types of alkaloids are known to be 
effective plant toxins. This class of compound is primarily restricted to Boraginaceae, 
Asteraceae, Fabaceae, and Orchidaceae families (Roseman 2007). 
 
4.1.2.6 Liquid- Liquid extraction of the API 
Liquid–liquid extraction, also known as solvent extraction and partitioning, is a 
method to separate compounds based on their relative solubility in two different 
immiscible liquids, usually water and an organic solvent. It is an extraction of a 
substance from one liquid into another liquid phase (Berthod & Carda-Broch 2004). 
This technique was employed in an attempt to separate the compounds in the API 
(precipitate) and the flow diagram followed towards this end is shown below as Flow 
Diagram 11. 
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Flow diagram 11: Illustration of liquid-liquid partitioning of the API of L trigonus, the 
separation, isolation of compounds and anti-HIV activity of the organic layers (BuOH 
and MeOH). 
 
4.1.2.7 TLC profiling of the extracts (BuOH and MeOH)  
Anti-HIV screening revealed that the MeOH extract was a more active extract than 
the BuOH extract (see flow diagram 11 above). The TLC profile of BuOH revealed 
about nine (see fig 9 & 10) chemical components with relative high intensity whereas 
MeOH extract showed about five (see fig 8) with a low intensity. It was, thus, evident 
that the BuOH partitioning process extracted more compounds from the API than 
MeOH. That could be the reason why it was less active than MeOH, while another 
reason could be the compounds that were responsible for the anti-HIV were probably 
in low concentration in the BuOH extract.  
3 g/70 ml of precipitate (API) 
L/L partitioning (100 ml MeOH, 100 ml 
EtOAc, 10 ml AcOH) 
MeOH extract 
Aqueous extract 
Separate layers 
TLC Profile & 
Bioassay 
IC 50 = 3.28 µg/ml  No further work 
Mixture of 5 compounds 
BuOH extract 
L/L partitioning (100 ml BuOH, 100 ml 
EtOAc, 10 ml AcOH) 
TLC Profile & 
Bioassay 
IC 50 = 19.9 µg/ml  
 
Mixture of more than 9 compounds 
Prep TLC (CHCl3: MeOH: AcOH) 
Poly 
phenol 
Poly 
phenol 
Fatty 
acid 
Poly 
phenol 
Fatty 
acid 
Poly 
phenol 
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Figure 8: MeOH extract profile, TLC plate A, under UV lamp. TLC plate B, exposed 
to ammonia vapour for 15 min. 
 
 
 
 
 
 
 
 
Figure 9: Separated compounds (labelled on the plates as 2,A2,C2,EA, 
EB,B,C,D1,D2,D3,F) from BuOH extract by prep TLC, plate (i) & (ii) were sprayed 
with vanillin and plate (iii), exposed to ammonia vapour (see chapter 7 for detailed 
methodology) 
 
 
 
A 
B 
i ii iii 
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Figure 10: BuOH fractions from VLC column, TLC plate sprayed with ninhydrin (see 
chapter 7 for further details) 
 
It was, therefore, concluded that BuOH extract should be purified further to isolate 
compounds. That inference was based on the fact that it had a better yield than 
MeOH. Compounds in the MeOH extract could not be separated even though it had 
a better activity. Prep TLC technique was employed to separate the chemical 
constituents showed on the plates above (fig 9 & 10). That brought about seven pure 
compounds being isolated but from the seven, only one compound was structurally 
elucidated (rosmarinic acid (BP36-117-26503-2), fig 12). BuOH extract was always 
used as the reference sample (labelled as “crude” on the TLC plate) in tracing the 
impurities on the pure compounds and/or fractions. 
 
4.1.2.8 Nuclear magnetic resonance and its application 
Nuclear Magnetic Resonance (NMR) spectroscopy is an analytical chemistry 
technique used in quality control and research for determining the content and purity 
of a sample as well as its molecular structure. For example, NMR can quantitatively 
analyze mixtures containing known compounds. For unknown compounds, NMR can 
either be used to match against spectral libraries. Once the basic structure is known, 
NMR can be used to determine molecular conformation in solution as well as 
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studying physical properties at the molecular level such as conformational exchange, 
phase changes, solubility, and diffusion. 
 
The in-house NMR Facility is currently home to four solution-state NMR 
spectrometers: Varian 400, 500, and 600 MHz spectrometers and a Bruker 800 MHz 
spectrometer. All spectrometers are equipped with multiple solution-state NMR 
probes for direct or indirect detection of 1H/19F and low frequency nuclei such as 13C, 
31P, and 15N. The 600 and 800 MHz spectrometers are also each equipped with a 
cryoprobe. This technique is used to identify and/or elucidate detailed structural 
information about chemical compounds. For example: 
 Determining the purity of medicines before they leave the factory 
 Identifying contaminants in food, cosmetics, or medications 
 Challenging small molecule projects, such as studies of low-quantity of natural 
products 
The principle behind NMR is that many nuclei have spin and all nuclei are electrically 
charged. If an external magnetic field is applied, an energy transfer is possible 
between the base energy to a higher energy level (generally a single energy gap). 
The energy transfer takes place at a wavelength that corresponds to radio 
frequencies and when the spin returns to its base level, energy is emitted at the 
same frequency. The signal that matches this transfer is measured in many ways 
and processed in order to yield an NMR spectrum for the nucleus concerned 
(http://www.chem.ucsb.edu/facilities#nmr). 
 
4.1.2.9 Acetylation reaction of the API 
The last attempt to purify the API was to acetylate and hydrolyse the API. This was 
achieved by treating 2.5 g of the API with acetic anhydride and pyridine for 12 hrs. 
The reaction mixture was then poured over in a mixture of ice H2O-chloroform and 
re-extracted. The layer of interest was the chloroform (CHCl3) layer, which was then 
evaporated to yield 1.8 g of a crude chloroform fraction. 
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A) Acetylation step 
 
B) Extraction step  
 
 
C) Base hydrolysis reaction 
 
Figure 11: Summary of the acetylation reaction process 
 
BP36-117-26504-A 
BP36-117-26504-C + 
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4.2 Results and Discussion 
From the above analyses, it was decided that the BuOH extract should be the one 
selected for further purification. All the general spraying reagents, ninhydrin, iodine, 
ammonia vapour and vanillin tested positive showing the presence of polyphenols, 
fatty acids and alkaloids in the BuOH extract (see fig 9 and 10 above). 
 
To separate these compounds EtOAc: MeOH: DCM: FA and CHCl3: MeOH: AcOH 
solvent systems were utilised during preparative thin layer chromatography (prep 
TLC) of the extract. The seven isolated compounds were identified as four 
polyphenols and three alkaloids. They were analysed using NMR and UPLC-MS 
However, only one compound was fully elucidated and characterised and it was 
identified as Rosmarinic Acid (RA) which is a known compound from the 
Boraginaceae family but to the best of our knowledge, it has never been reported 
from L. trigonus. The structure of this compound is shown in Figure 12 below. 
 
 
 
 
 
 
 
 
 
Figure 12: Compound BP36-117-26503-2 
 
Rosmarinic acid is a well-known polyphenol which has been previously reported as 
an anti-oxidant and antiviral agent. Originally identified in rosemary (Rosmarinus 
officinalis L.), the structure was elucidated as an ester of caffeic acid and 3-(3, 4-
dihydroxyphenyl) lactic acid (Bhatt et al. 2013).  
 
This compound has also been reported to occur in several taxonomically non-related 
families of the plant kingdom. It has attracted much attention since it was identified to 
be the main compound responsible for the antiviral activity of lemon balm in treating 
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Herpes simplex (Toth et al; 2003). In the present study compound BP36-117-
264503-2 (identified as Rosmarinic acid) showed weak anti-HIV activity with an IC50 
value of 111 µg/ml.  
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Table 4: Summary of the anti-HIV results of the isolated compounds from the Liquid-
liquid partitioning chromatography  
 
 
 
 
SAMPLE NAME 
 
 
PURITY 
 
 
SOLVENT 
 
IC50 
(µg/ml) 
 
METHOD 
BP36-117-26464C 
(API) 
mixture Water  0.04 EtOH 
precipitation 
BP36-117-26504-
MeOH extract 
mixture Water 3.26 Liquid-liquid 
extraction 
BP36-117-26504-
Acetone/H2O 
mixture DMSO 8.83 PVPP extraction 
BP36-117-26504-
Butanol extract 
mixture DMSO 19.9 Liquid-liquid 
extraction 
BP36-117-26503-2 Polyphenol 
(pure) 
DMSO 111 Prep TLC 
BP36-117-264504-EB Semi pure DMSO 357.31 Prep TLC 
BP36-117-264504-C2 Semi pure DMSO 242.88 Prep TLC 
BP36-117-264504-A2 pure DMSO 310.43 Prep TLC 
BP36-117-264504-EA pure DMSO 496.89 Prep TLC 
BP36-117-264504-DE2 alkaloid 
(pure) 
DMSO 85.24 Prep TLC 
BP36-117-264504-F Polyphenol 
(pure) 
DMSO 22.24 Prep TLC 
BP36-117-264504-
(acetone 1) 
Alkaloid 
(pure) 
DMSO  486.54 Prep TLC 
BP36-117-264504-
(50% MeoH/Water) 
Alkaloid 
(pure) 
DMSO 473.42 Prep TLC 
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4.3 Isolation of alkaloids in the API 
The alkaloids isolated in this present study could not be confirmed as pyrrolizidine 
alkaloids. Flow diagram 12 below illustrates clearly how the API was purified through 
Liquid-liquid partitioning and ultimately isolating three alkaloids shown on a TLC 
plate below - please see Figure 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow diagram 12: Indicating the step-by-step isolation of the alkaloids in the API 
Separate layers 
K, M, N combined for prep TLC 
3 g/100 ml dH2O Spray dried extract 
L/L partitioning (100 ml BuOH, 100 ml 
EtOAc, 10 ml AcOH) 
BuoH extract 
Aqueous extract 
TLC Profile & 
Bioassay 
IC 50 = 19.9µg/ml  No further work 
Collected 5 fractions per 
eluent 
VLC, eluted with MeOH, 
EtOH, EtOAc, Acetone, 
CHCl3, DCM& Water 
29 fractions, 
NMR & TLC Similar fractions 
combined 
Purification of 
fractions 
10 fractions, 
NMR & TLC 
Alkaloid 3 -(IC 50. = > 
100(µg/ml)) 
 
TLC of Fraction A, B, C, K, M & N  
Bioassay, NMR & TLC 
Compounds were not elucidated – needs 
further analyses  
Alkaloid 2 -(IC 50. = 
> 100(µg/ml)) 
 
Alkaloid 1-(IC 50. 
= > 100(µg/ml)) 
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Figure 13: A TLC plate showing 3 alkaloids (three arrows pointing at three spots) 
that were determined using CHCl3 (40): MeOH. (60)  
 
The structural elucidation of the three alkaloids could not be determined due to the 
complexity of their structures. 
 
4.4 Acetylation of the API 
Section 4.2.5 describes this process broadly (see fig 11). The chloroform fraction 
was partitioned on silica gel and two major compounds were isolated using a 
Hexane: EtOAc (8:2) solvent mixture. The TLC plate was developed in Hex: EtOAc 
(6:4) solvent system. The two compounds were identified as methyl pentacetate 
(BP36-117-26504-A) and sucrose derivative/s (BP36-117-26504-B). The isolated 
compounds were then hydrolysed, to replace the acetates by OH groups resulting in 
two well-known compounds called Bornesitol or methyl inositol (BP36-117-26504-C) 
(fig 14) and sucrose in their pure form. They were then screened for anti-HIV activity. 
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The results showed no activity (an IC50 value of >500 µg/ml which was equated as no 
activity) from these compounds.  
 
 
 
 
Figure 14: Compound BP36-117-26504-C 
 
In trying to purify and separate all these compounds in the API, it appeared that 
these compounds may be inter-dependent or reliant on one another to produce 
significant anti-HIV activity, something that was experienced during the preliminary 
purification of the API (section 2.3.1). This could explain why it was not possible to 
purify the API and still retain the same magnitude of activity. There was no 
advantage in trying to separate the compounds in the API for formulation into a 
microbicide since formulations into a gel and caplets would be conducted using the 
API as a whole. Separation and isolation of the compounds in the API was attempted 
so that all the classes or individual compounds in the API can be identified. 
 
4.5 Molecular characterization of the API  
This section will provide details regarding the characterization of the API and the 
isolated compounds. Since it was discovered that the API was a big polymeric 
molecule, it was difficult to fully characterize it as it needed specialized techniques. 
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However, the isolated compounds and the API were partially characterized by NMR, 
GC and UPLC-MS / TOF MS ESI and HPLC-ESI. 
 
4.5.1 Mass spectroscopy 
Compound BP36-117-264503-2 (Fig 12) was isolated as a yellow semi-solid powder. 
The TOF MS-ESI (chromatogram 3) showed a molecular ion [M-H] – peak at m/z 359 
corresponding to a molecular formula C18 H16O8. This compound was identified as 
the known compound called rosmarinic acid. A standard of rosmarinic acid was 
purchased from Sigma-Aldrich for comparison. Mass spectrometer (MS), thin layer 
chromatography (TLC) (fig 15) and NMR (spectrum 1 and 3) of the standard 
provided a 100% match with the compound BP36-117-264503-2 (see chromatogram 
3 below).  
 
 
Figure 15: TLC plate of Rosmarinic acid (right spot) and BP36-117-264503-2 (left 
spot) 
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Chromatogram 3: TOF MS-ESI profile of Rosmarinic acid and BP36-117-264503-2 
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BP36-117-26504-C was also analysed through High Resolution Mass spectrometry 
(MS). It showed a molecular ion peak of 194 g/mol corresponding to the molecular 
formula C7H14O6. This compound was identified as the known compound bornesitol 
which to the best of our knowledge has never been isolated from this plant species 
before. 
The API, on the other hand, was analysed using high resolution mass spectrometry 
and found to have a molecular weight in the region of 10 – 20 kDa. In the current 
form (active precipitate), it was considered difficult to develop the API as an oral 
treatment for HIV, as high-molecular weight agents often have poor bioavailability 
following oral administration.  
However, large molecules with potent anti-HIV activity are ideal for topical use and 
potent development as a microbicide. Unlike the other carbohydrate microbicides 
which have poor anti-HIV properties (Balzarini 2007), L. trigonus produced an API 
with significant anti-HIV activity and was demonstrated to be ideal to be used 
topically as a microbicide (See chapter 5 for microbicide formulation studies). 
 
4.5.2 HPLC-ESI 
Polymerization is a process of reacting monomer molecules together in a chemical 
reaction to form polymer chains or three-dimensional networks. To confirm if there 
was any degree of polymerisation in the API, it was compared with two other 
polymers (poly-galacturonic and galacturonic acid), using HPLC-ESI. 
 
4.5.2.1 Method 
This was carried out by extracting the aerial plant parts in boiled and cold water. The 
aqueous extracts (potential API’s) were collected at different times (T0 –T4) i.e. 5 
samples were collected  
Five grams of the aerial plant parts was extracted using 100ml of hot water at 90°C. 
Five samples were collected at 2 hours different intervals. i.e. T0, T1…T4. 
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Two millilitres (2 ml) of each sample was analysed immediately using HPLC-ESI. 
The same was done for the cold extracts, performed at 4°C with cold distilled water. 
Below are the chromatograms showing how the API behaves after a long extraction 
(cold and hot water). 
 
4.5.2.2 Results 
The negative ion mode was more sensitive as it revealed more constituents and a 
better separation profile after a prolonged extraction. The more time the aerial parts 
of the plant were soaked in water (cold or hot), the more it polymerised (i.e. by the 
number of peaks appearing in the lower retention region of the chromatogram of T1 – 
T4). This also explained the differences in the activity between the extracts prepared 
from the processed (oven dried at 80°C and ground) and unprocessed aerial parts of 
the plant (fresh leaves and stems) please refer to chapter 3, section 3.1.1.2 for 
further details. 
The HPLC chromatogram (see chromatogram 4 below) revealed that something was 
happening after at least 2 hours of extraction, as more peaks or components 
appeared. The API was compared with a galacturonic acid, which was assumed to 
be the main polymer it contained. This polymer was found to be present in massive 
amounts although it exhibited no anti-HIV activity. It had a retention time of between 
10 – 15 minutes. See chromatograms below. 
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Chromatogram 4: ESI- negative ion of the hot extract  
 
 
 
 
 
 
 
 
 
 
Hot aqueous extracts – negative mode 
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Chromatogram 5: ESI- negative ion of the cold extract 
 
 
Cold extracts – negative mode 
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Chromatogram 6: ESI- negative ion of the three standards (polymers) and the blank 
 
4.5.3 Gas chromatography of the API 
Gas chromatography (GC) has been used as a powerful qualitative and quantitative 
tool for carbohydrate analysis. Prior to analysis by GC, compounds containing 
functional groups with active hydrogens such as COOH, OH, NH, and SH needed to 
be protected and converted into volatile derivatives, amenable to GC analysis. 
Compounds with these functional groups tend to form intermolecular hydrogen 
bonds, reducing volatility (Guan et al; 2010). 
The current study describes a method for the qualitative and quantitative 
determination of free carbohydrates and polysaccharides in the API by GC. Their 
saccharide content was also compared. This was achieved through methanolysis 
Poly-galacturonic acid 
Galacturonic acid 
Blank 
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and silylation of five monosaccharides, namely, arabinose, xylose, mannose, 
glucose, galactose and mannitol as the internal standard and also two polymers 
namely, glucuronic acid and galacturonic acid. 
 
4.5.3.1 Methanolysis and Silylation process 
During silylation which is the most widely used derivatisation scheme for GC, 
trimethylchlorosilane (TMCS), which is known to be the simplest reagent, was used 
in conjunction with HMDS and pyridine to improve the silylation of sugars and related 
compounds. 
The results showed that the API (precipitate) contained more than 30% of 
carbohydrate content with galacturonic acid dominating at 36.3%. Please note the 
results in Table 5. Gas chromatography analysis also proved the API chemical 
composition to be the same as that of apple pectin. Please note chromatograms 7, 8 
and 9. Galacturonic acid is the major component of pectin, which also explains why 
galacturonic acid is seen as the major compound in the API even though it does not 
have any anti-HIV properties. The order of how these sugars are held together in the 
API is still to be investigated. 
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Table 5: GC analysis of the API, illustrating the carbohydrates content. 
 
Name % of total carbohydrate  Description 
Arabinose 11.5 Monosaccharide 
Rhamnose 5.5 Monosaccharide 
Xylose 1.9 Monosaccharide 
Galactose 10.5 Monosaccharide 
Glucose 26 Monosaccharide 
Mannose 4 Monosaccharide 
Glucuronic acid 4.3 Polymer 
Galacturonic acid 36.3 Polymer 
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Chromatogram 7: GC chemical profile of the API 
 
 
Chromatogram 8: Apple pectin 
4 .0 0 6 .0 0 8 .0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0 2 2 . 0 0 2 4 . 0 0 2 6 . 0 0 2 8 . 0 0 3 0 . 0 0 3 2 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
8 5 0 0 0 0 0
9 0 0 0 0 0 0
9 5 0 0 0 0 0
T im e - - >
A b u n d a n c e
T IC :  B i o _ 0 3 .D \ d a ta .m s
 6 . 9 8 2
 7 . 4 3 7 8 . 2 3 8 8 . 6 3 7 9 . 3 3 0 9 . 7 9 81 0 . 4 3 71 1 . 4 0 11 2 . 2 7 51 3 . 6 5 51 5 . 2 3 31 6 . 5 3 51 7 . 0 8 51 7 . 8 5 31 8 . 8 3 7
1 9 . 7 0 5
2 3 . 9 3 8
2 5 . 6 7 32 6 . 5 1 8
2 7 . 9 7 9
2 9 . 5 6 03 0 . 4 7 83 1 . 3 5 33 2 . 2 4 5
4 .0 0 6 .0 0 8 .0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0 2 2 . 0 0 2 4 . 0 0 2 6 . 0 0 2 8 . 0 0 3 0 . 0 0 3 2 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
8 5 0 0 0 0 0
9 0 0 0 0 0 0
9 5 0 0 0 0 0
T im e - - >
A b u n d a n c e
T IC :  B i o _ 0 1 .D \ d a ta .m s
 6 . 9 8 0 8 . 2 3 5 8 . 6 2 7 9 . 3 3 4 9 . 7 9 01 0 . 6 9 21 1 . 3 6 31 2 . 2 5 41 3 . 9 0 51 4 . 6 6 31 5 . 2 2 21 6 . 5 2 41 7 . 0 7 71 7 . 8 3 2
1 8 . 8 2 91 9 . 6 9 5
2 0 . 5 6 9
2 1 . 0 6 5
2 3 . 9 2 7
2 5 . 6 2 02 6 . 1 3 22 7 . 9 6 8
3 0 . 5 5 7
Pectin 
Pectin  
Profile of the API 
Profile Apple pectin  
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Chromatogram 9: Poly-galacturonic acid 
 
 
 
 
 
 
 
 
 
 
Poly-galacturonic acid profile 
4 .0 0 6 .0 0 8 .0 0 1 0 . 0 0 1 2 . 0 0 1 4 . 0 0 1 6 . 0 0 1 8 . 0 0 2 0 . 0 0 2 2 . 0 0 2 4 . 0 0 2 6 . 0 0 2 8 . 0 0 3 0 . 0 0 3 2 . 0 0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
2 5 0 0 0 0 0
3 0 0 0 0 0 0
3 5 0 0 0 0 0
4 0 0 0 0 0 0
4 5 0 0 0 0 0
5 0 0 0 0 0 0
5 5 0 0 0 0 0
6 0 0 0 0 0 0
6 5 0 0 0 0 0
7 0 0 0 0 0 0
7 5 0 0 0 0 0
8 0 0 0 0 0 0
8 5 0 0 0 0 0
9 0 0 0 0 0 0
9 5 0 0 0 0 0
T im e - - >
A b u n d a n c e
T IC :  B i o _ 0 2 .D \ d a ta .m s
 6 . 9 8 7 8 . 2 3 8 9 . 7 9 41 0 . 7 1 11 1 . 3 6 41 2 . 2 7 11 3 . 8 7 41 5 . 2 2 71 7 . 0 8 41 7 . 8 4 31 8 . 8 2 4
1 9 . 7 0 5
2 1 . 0 6 5
2 2 . 1 5 5
2 3 . 2 7 9
2 3 . 9 1 6
2 4 . 6 5 5
2 5 . 6 1 7
2 6 . 5 1 12 7 . 9 7 8
2 9 . 5 5 73 0 . 6 0 33 1 . 4 23 1 . 8 4 62 . 3 8 13 . 7 2 1
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4.5.4 Structural elucidation of compound, BP36-117-26503-2 
 The NMR data of compound BP36-117-26503-2 is indicated in Figure 12, and is 
collated in Table 6. The 13C NMR spectrum of this compound displayed (spectrum 4) 
a total of eighteen carbon signals. One CH2 carbon, eight CH carbons, and seven 
non-protonated carbons were identified.  
Two dimensional (2D’s) NMR experiment, gHSQC, gCOSY, gHMBC allowed the 
correlation of all protonated carbon atoms with well-resolved protons and 
correlations between protons. From this information there was a construction of the 
structural fragment of the compound and later was confirmed to be rosmarinic acid, a 
known polyphenol. The proton (1H) NMR spectrum of this compound (spectrum 3) 
displayed signals with chemical shifts and coupling constants comparable with 
literature data for rosmarinic acid.  
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Table 6: 13C and 1H NMR spectral data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d- doublet, dd – double of doublet 
 
Literature, CD3OD  
Bruker Avance 500 MHz 
(Rosmarinic acid) 
Experimental, CD3OD 
Varian 600MHz 
(BP36-117-26503-2) 
13C (δ) 1H (δ) 13C (δ) 1H (δ) 
174.3 7.52, 1H, d 178.6, C-9 7.51, 1H, d, H-7’ 
169.4,  7.04, 1H, d 170.3, C-9’ 7.01, 1H, d, H-2’ 
149.5 6.91, 1H, dd 150.5, C-4’ 6.90, 1H, dd, H-6’ 
145.7 6.75, 1H, d 147.9, C-7’ 6.75, 1H, d, H-5’ 
145.0 6.70, 1H, d 147.8, C-3 6.65, 1H, d, H-2 
144.9 6.69, 1H, d 147.1, C-4 6.61, 1H, d, H-5 
143.2 6.57, 1H, dd 146.0, C-3’ 6.60, 1H, dd, H-6 
130.4 6.26, 1H, d 132.4, C-1 6.26, 1H, d, H-8’ 
128.2 5.19, 1H, dd 129.2, C-1’ 5.08, 1H, dd, H-8 
122.2 3.0, 1H, dd 124.1, C-6 3.1, 1H, dd, H-7a 
121.4 3.00, 1H, dd 123.0, C-6’ 2.98, 1H, dd, H-7b 
117.6  118.7, C-2  
116.3  117.7, C-5  
116.1  117.4, C-5’  
115.8  116.9, C-8’  
115.3  116.4, C-2’  
77.8  78.9, C-8  
38.9  40.0, C-7  
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4.5.5 Structural elucidation of compound (BP36-117-26504-C) 
The NMR data of compound BP36-117-26504-C (fig 14) is summarized in Table 7. 
The 13C NMR spectrum of this compound (spectrum 7) displayed a total of seven 
carbon signals with 6 CHs and one OCH3. The proton (1H) NMR spectrum of this 
compound (spectrum 6) displayed signals with chemical shifts and coupling 
constants comparable with literature data for bornesitol.  
 
Table 7: 13C and 1H NMR spectral data for BP36-11-26504-C (fig 14) and bornesitol 
(Ichimura, 1998) 
 
 
 
 
 
 
 
 
 
 
 
 
4.6 Conclusion 
After the API was partially characterized, about 57 g of it was produced for the 
development and formulation of the API into a microbicide. The active ingredient 
(BP36-117-26464C) in the spray dried extract (aqueous extract) was isolated and 
concentrated through an ethanol precipitation process. The plant drying process was 
Experimental in D2O Literature in CD3Cl 
13C (δ) 1H (δ) 13C (δ) 1H (δ) 
80.41 3.1, 1H, dd 80.52 3.19, dd 
67.36 4.2, 1H,t 67.66 4.29, 1H, t 
70.98 3.39, 1H, dd 71.09 3.48, 1H, dd 
72.17 3.3, s 72.28 3.26, 1H, s 
74.33 3.5, 1H, t 74.45 3.61, 1H, t 
71.55 3.18, 1H, t 71.65 3.19, 1H, t 
56.62  56.72  
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shown to contribute significantly to the formation of this API i.e. oven drying and 
grounding the aerial plant parts (chapter 3). 
The API production method was optimised and refined, with the energy-intensive 
spray drying process being eliminated. The precipitate, which has been identified to 
consist of galacturonic acid and other small compounds, has shown potency against 
several HIV clinical isolates which was comparable and in certain cases better than 
T20 and Tenofivir, which are two commercial anti HIV drugs. 
 
The biggest challenge in this present study has been the characterisation of the API 
as it is a complex carbohydrate with a high molecular weight. Although it is not 
critical to completely characterise the API, further preclinical work such as the 
release studies (chapter 5) are dependent on a means of detecting and quantifying 
the API. Due to its polymeric nature, the profiling of the API using standard analytical 
methods was not feasible. Several alternative techniques were investigated. 
Ultimately a method was developed that relies on the methanolysis of the API with 
the subsequent formation of silyl derivatives which were then analyzed by Gas 
Chromatography. Please see details of this in section 4.5.3.1. 
 
Since the API also contains a large percentage of galacturonic acids, which are the 
building blocks of pectin, it was decided to compare the chemical profiles of 
polygalacturonic acid, apple pectin, citrus pectin, and galacturonic acid with that of 
the API. This polymeric material (API) was found to be very similar in chemical 
composition to apple pectin. Please see chromatograms 7, 8 and 9 indicating this. 
 
Neither apple pectin nor polygalacturonic acid were found to have anti-HIV activity, 
so even if they are similar in chemical composition with the API, it doesn’t mean 
these are responsible for anti-HIV activity in this plant. It is possibly the unique 
folding of this polymer or its metameric character that is responsible for the activity of 
the API. 
 
Since the chemical composition of the API was similar to that of apple pectin and yet 
the pectin showed no ant-HIV activity, this required further investigation of the other 
components present in the API. For that purpose, chromatographic techniques were 
employed and four classes of compounds were detected phytochemically, that led to 
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isolation of eight compounds (1 methyl cyclitol, 3 alkaloids and 4 polyphenols). Due 
to complexity of the structures, only two compounds (Rosmarinic acid and 
Bornesitol) were structurally elucidated as noted in Figures 12 and 14. 
 
The API was, therefore, shown to be a mixture of several small molecules and pectin 
as the major polymer. The presence of pectin in the API was first suspected when it 
showed a tendency of gelling (during the dissolution). Globally, pectin is known as 
the gelling agent. The suspicions were later proved during GC analysis by comparing 
their profiles. Their chemical composition was more or less the same. The eight 
other compounds that were isolated from the API all showed very weak activity as 
noted in Table 4. It was, therefore, concluded that all these compounds in the API 
contribute towards activity, which could explain why the more the API was purified 
the more it lost activity. 
 
As the main aim of the present study was to identify the best active phyto- 
pharmaceutical ingredient (API) for further microbicide development into gels and 
caplets, the conclusion is that this would be the precipitate BP36-117-26464C.  
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CHAPTER 5: CONTRIBUTION OF THE STUDY 
5. Development of the API (BP36-117-26464C) as a microbicide 
5.1 Microbicides 
The main aim of the present study was to isolate and characterize the API from 
Lobostemon trigonus, a plant used by a private traditional healer (TH) in the Eastern 
Cape region of South Africa, in order to facilitate its development as a microbicide.  
Microbicides must meet certain standards in terms of colour, cost effectiveness of 
production and must be odourless, etc. This chapter will describe the methods used 
to remove the colour of the API and will provide a summary of the last stages of the 
development of the API as a microbicide.  
The ultimate product (microbicide) will eventually help women to protect themselves 
from sexual transmission of HIV and other STI’s. The best and most active API was 
selected based on the efficacy i.e. the precipitate named BP36-117-26464C with a 
determined IC50 value of 0.04 µg/ml as discussed in Chapter 3. A large-scale batch 
of the precipitate was prepared for this purpose and half of it was decolourised for 
gel formulation while the other half was stored for caplet formulations. These 
processes will be discussed in further detail below. 
 
5.1.1 Microbicide formulations 
As the number of HIV-infected women escalates worldwide, vaginal microbicides 
may help slow the spread of HIV/AIDS. In terms of HIV prevention, a microbicide is a 
product which is designed to be applied to the vagina or the rectum, in order to 
reduce the user’s risk of HIV infection when HIV exposure occurs. While potential 
microbicides have most often been developed as gels or creams (similar to a 
lubricant), they could be developed in a number of different formulations (a coating 
for a condom, anal douches, tablets or pieces of film, vaginal rings or gels) (Obiero 
et al; 2012). 
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5.1.2 Pre-steps taken before development of the API into a microbicide 
5.1.2.1 Decolourisation of the API 
For the API to be developed and formulated into a gel, the dark brown colour of the 
API required removal. Different “decolourisation” techniques were used i.e. activated 
charcoal, MgSO4, 7000, 10 000 & 12 000 dialysis membranes and a polymer, PVPP. 
These different techniques were all investigated and the best technique was selected 
based on the highest activity shown in the anti-HIV assay.  
 
5.1.2.2 Gel formulation of the API 
Topical gel preparation has remained one of the most popular and important 
pharmaceutical dosage forms. As a result, the therapeutics effects of the drugs are 
achieved effectively whereas the systemic side effects can be avoided or minimized. 
The formulation of an effective gel requires the use of an appropriate gelling agent, 
usually a polymer.  
The preferred characteristics of such polymer include their inertness, safety, and 
biocompatibility with other ingredients, good adhesion to mucous membrane, and 
permission of drug permeation while not being absorbed into the body, irritation-free 
and preferably decomposable. When in the formulation, the polymer should exhibit 
good swelling, syneresis and rheological properties suitable for solidifying the system 
(Abrar et al; 2012). 
Material Science and Manufacturing (MSM) have been involved in the formulation of 
the API into a classical microbicide gel. The dark colour of the API and the possible 
poor aesthetic appeal of this as a vaginal microbicide, led to a concerted effort to 
further purify/decolourise the API. MSM then focused their efforts on the formulation 
of the gel with the decolourised/purified form of the API and the characterisation 
thereof (rheological studies, shelf-life and stability, etc.), which was comparable with 
that of the coloured gel.  
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Besides the dark colour of the API posing a deterrent for further development, there 
was also the issue of compliance with a gel microbicide formulation. Hence, it was 
decided to prepare the gel for demonstration purposes only and not to pursue with 
the irritancy studies on this formulation and to rather focus on an alternative 
formulation (i.e. the caplet) which has a better chance of clinical success. 
 
5.1.2.3 Caplet formulations of the API 
As contraceptive technology has evolved, research on microbicide formulations and 
delivery now includes new formulation platforms for strategies able to provide 
protection against HIV infection even during unanticipated sex. These include slow-
release intra-vaginal rings made of silicone or thermoplastic urethane, loaded with 
the API within the ring matrix or in a reservoir at its centre that could remain in situ 
for weeks or months (Buckheit et al; 2010). 
The choice of delivery system depends on many factors, including the following: 
• Active ingredient to be delivered 
• Amount of active ingredient to be delivered 
• Means or route that ingredient is to be delivered 
• To which sites, at what rate, over what period of time, and for what purpose 
The collaboration involving the University of Witwatersrand led to the development of 
a slow release intra-vaginal caplet technology incorporating the API and AZT. This 
allows the application of a dual-mechanism microbicide formulated into a caplet into 
the vagina, which can then last up to 72 days without application on a daily basis 
(Buckheit et al; 2010). 
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5.2 Methods and Materials 
5.2.1 Decolourisation of API 
Firstly, 50 g of activated charcoal was mixed with 10 g/400 ml of the API (IC50 = 0.04 
µg/ml), in distilled water. The mixture was washed through a vacuum filter with 700 
ml of lukewarm distilled water. The residue (charcoal) was decanted and the filtrate 
(colourless API) was freeze dried. The amount of the activated charcoal was 
reduced because; primarily the amount of charcoal used was too much and it was 
thought to have an impact on the activity but still the decolorized API was shown to 
have lost activity. This is shown in Table 8. 
The second technique made use of MgSO4 where four batches of 500 mg/100 ml of 
the API (precipitate) were treated with 1000 mg, 500 mg, 250 mg, and 25 mg of 
MgSO4. The mixture was centrifuged and the salts formed were removed through 
dialysis. The colourless filtrate (API) was freeze dried (fig 16 (A)) and screened for 
anti-HIV activity.  
A third decolourisation technique involved the use of dialysis where three separated 
20ml aliquots of the API (precipitate) were dialysed through two membranes (7000, 
10 000 & 12 000) membranes, using 1L of water as the medium. As for the PVPP, it 
was used as indicated in chapter 4, section 4.1.2.6. 
 
5.2.2 Assaying of API against Herpes Simplex Virus 
The HSV-1 assay is based on the ability of Herpes Simplex type 1 virus (HSV-1) to 
cause cytopathic effects (CPE) in Vero cells. The changes in cell morphology caused 
by infecting virus are called cytopathic effects (CPE). Compounds of interest (API) 
should be effective against formation of CPE on cells in the presence of virus. In this 
study, the cytopathic effect inhibitory method previously described by (Schmidtke et 
al; 2001) was used to evaluate antiviral activity of the API labelled as “BP36 
precipitate and plant extracts (table 10). 
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5.3 Results and Discussion 
5.3.1 Effects of decolourisation on anti-HIV Activity 
All the decolorized API’s were subjected to a bioassay and the results of these 
assays are shown on Table 8 below. 
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Table 8: Anti-HIV results of the decolourised API using different decolourisation 
techniques 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Decolourisation 
technique 
Sample of 
interest 
 HIV 
strain 
IC50 (µg/ml) 
Reference 
sample 
API (BP36-
117-26464C) 
HXB2 0.04 
Activated 
charcoal 
decolourised
API  
HXB2 >100 
7000 MW 
Dialysis 
membrane 
 
decolourised
API  
HXB2 0.8 
10 000 MW 
Dialysis 
membrane 
decolourised
API 
 
HXB2 0.08 
12500 MW 
dialysis 
membrane 
decolourised
API 
 
HXB2 0.2 
MgSO4  decolourised
API 
 
HXB2 10.82 
PVPP decolourised
API 
HXB2 0.3 
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All the decolourised API’s treated with MgSO4 as described above also exhibited no 
activity except for the batch treated with 25 mg of MgSO4 which showed significant 
activity (IC50 = 10.82 g/ml). After the method was revised and the amount of MgSO4 
was reduced further, the decolorised API’s showed an improved activity but the 
colour did not improve. It was then concluded that the more MgSO4 added, the more 
the API loses its activity. The use of this technique was discontinued as it was going 
to be time consuming to decolourise little by little, since more than 30 g was the 
target for the formulation of the API. For that reason, MgSO4 was eliminated as the 
decolourising agent, even though it was inexpensive. 
The problem with the dialysis was that the API had a tendency to gel, because of the 
presence of pectin, and this blocked the membranes so that colour removal could 
not be achieved. There was not much of a diffusion reaction happening after 
blockage as anticipated. All the residue and filtrates were recovered and screened. 
As expected, the residue retained its dark colour and activity. Please note the results 
indicated in Figure 16 (D) and Table 8. 
The last technique used Polyvinylpolypyrrolidone (PVPP), a polymer which can also 
be used to extract polyphenols from the crude extract as discussed in Chapter 4. 
This technique worked well as PVPP removed the colour from the API and when the 
decolourised API was screened for anti-HIV activity it showed good activity (IC50 = 
0.3µg/ml). This compares to the activity of the API before the colour was removed 
(IC50 = 0.04 µg/ml). This method was optimized and it showed consistent results in 
terms of efficacy but the removal of the colour was not complete. 
As indicated, when PVPP was used for API decolourisation, most colour was 
removed from the API but there was an associated decrease in anti-HIV activity. This 
indicates that some other anti-HIV compounds were removed, possibly by adsorption 
to the PVPP. To test this, the PVPP residue was subjected to liquid-liquid (L/L) 
partitioning to extract all the possible compounds that were adsorbed by the PVPP. 
The PVPP residue was indeed shown to contain compounds that were ultimately 
separated by L/L partitioning and TLC, some of which showed marginal anti-HIV 
activity. Details of this are provided in Chapter 4. 
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Figure 16: Decolourized potential API’s. A is the API (white samples) treated with 
MgSO4; B, API without any treatment; C, API with PVPP (light brownish) and D, 
dialyzed API (dark brown) using 10 000 and 7 000 MW membranes. 
 
5.4 API as a potential microbicide candidate 
For the development of an API into a gel or caplet formulation, grams of the API are 
required. In this study, more than 50 g of the API were prepared as it was important 
for the API to be repeatedly screened to test for reproducible anti-HIV activity. 
Several batches of the API were prepared and screened to show consistently high 
levels of activity (IC50 = 0.04 – 1.0µg/ml). The activity of the API BP36-117-26464C 
(0.04 µg/ml) against several HIV-1 subtype C pseudovirions compared favorably with 
that of T20 (0.02 µg/ml) and Tenofovir (0.40 µg/ml).  
As part of another MSc study, the API was also screened against 10 subtype C 
clinical isolates and showed anti HIV activity against most of these isolates. A “time 
of addition” assay indicated that the API acts during the early stages of HIV infection, 
similar to the T20 and Maraviroc entry inhibitors, and may act as an attachment 
inhibitor but that it appears to lose its ability to inhibit infection after viral attachment. 
The data suggest that API is a potent antiviral and that it may act as an attachment 
inhibitor. This mode of action supported its potential use as a microbicide (Van Den 
Berg et al; 2010). 
A 
B C 
D 
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5.4.1 Evaluation of the API against other viruses 
Herpes simplex viruses (HSVs) have a complex life cycle. Once the virus has 
infected the host, it persists for life as a latent infection that reactivates throughout 
the life span of the host. These viruses cause infections of the skin and mucous 
membranes of the mouth, eyes and genitals in humans. 
There are two types of HSV, HSV type 1 has traditionally been associated primarily 
with oral-facial infections, whereas HSV-2 is generally associated with a genital 
infections transmitted through sexual activity (Emami et al; 2009). There was a need 
for this particular assay to be conducted since this virus can also be transmitted 
through sexual activities. Other sexually transmitted viruses (like gonorrhea and 
HSV-2) are still to be investigated. Table 10 below provides results of the anti-HSV 
assay.  
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Table 10. Results of the screening of the antiviral activity of the API against HSV-1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample ID Sample 
description 
Extract 
type 
Showed activity 
(concentration) 
BP36 
precipitate 
(API) 
BP36-117-26464C 
H2O 
At 500 ug/ml 
BP36 Acetone 
H2O 
BP36-117-264504-
Acetone/ H2O 
30% 
Acetone in 
H2O 
Weak activity 
(>500) 
BP36 
Methanol 
BP36-117-264504-
MeOH Methanol 
At 500 ug/ml 
BP36 Butanol 
BP36-117-264504-
BuOH Butanol 
Weak activity 
(>500) 
Acyclovir  Internal standard purchased 5 ug/ml 
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BP36 precipitate (API) and methanol extracts (which was previously extracted 
through liquid-liquid extraction as described in Chapter 4 exhibited good antiviral 
activity at 500 ug/ml (% CPE inhibition >50%) against herpes simplex 1 virus. This is 
shown in Figure 17. The most active compounds are shown in sky blue (BP36 
precipitate, API), purple (methanol extract) and lastly green (acyclovir, the internal 
standard). Both the precipitate and the methanol extract unfortunately could not be 
compared with the standard, as it showed very good activity at the lowest 
concentration, whereas the API and the methanol extract only showed a cytopathic 
effect at a high concentration (500ug/ml), which is not a good indication. Pure 
compounds need to be screened individually as they might show different results. 
 
 
 
Figure 17: Antiviral activity of compounds at 500 ug/ml and 100 ug/ml and acyclovir 
(5 ug/ml) tested against Herpes simplex virus 2. 
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5.4.2 Formulations of the API  
Formulation studies were conducted by two CSIR Biosciences research 
collaborators. The University of the Witwatersrand (Wits), Department of Pharmacy 
and Drug Delivery Platform, South Africa is responsible for the caplet formulation of 
the API. The second group, the Material Science and Manufacturing (MSM) 
Research Group is from within CSIR, and is responsible for the gel formulation. 
To commence development of these formulations, both collaborators were provided 
with sufficient quantities of the API. For the gel formulations, a decolourised API was 
used, and for the caplet formulation the original isolated API (dark precipitate) was 
provided as there was no need to remove the colour of the API. 
 
5.5 Conclusions 
A suitable API has been identified, characterized accordingly and screened for anti-
HIV activity against both a pseudovirus and peripheral blood mononuclear cells 
(PBMCs). It has been found to be a suitable microbicide candidate but there are still 
other studies required before it can be commercialized. The summary of other in vivo 
or ex vivo and in vitro studies are listed below:  
 Evaluation against other STI’s e.g. HSV-2, gonorrhoea 
 Efficacy against other HIV strains in PBMC assay 
 Preclinical toxicity studies i.e. irritancy 
 pH stability 
 In vivo pig vagina study 
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CHAPTER 6: GENERAL CONCLUSIONS 
South Africa is a home to thousands of plant species, each an industry for unique 
and useful chemical compounds. Natural products and medicinal plants still remain 
an important starting point for drug discovery and the identification of novel anti- HIV 
agents. The historical success of natural products as anti- HIV agents and the large 
number of structurally diverse plant-derived compounds provide justification for the 
continued effort in this area. 
The objective of this study was to isolate, identify and characterize the active phyto-
pharmaceutical ingredients (API) from L. trigonus, a plant used traditionally to treat 
HIV. This active ingredient was ultimately going to contribute to the development of a 
microbicide, which will serve the purpose of empowering women to help protect 
themselves from sexual transmission of HIV. 
Chapter 1 discussed the global status of HIV/AIDS and its potential prevention and 
treatment tools. Since women are so vulnerable to HIV and are the most affected in 
the world, an alternative prevention tool against this virus was investigated. This led 
to the identification of the API, being the precipitate BP36-117-26464C. It was 
identified to consist of a large polymeric molecule with significant anti-HIV activity. 
The API was also subjected to other biological assays like herpes simplex virus 1. 
Chemical analysis of the API which included NMR analysis, HPLC profiling, UPLC-
MS and also GC analysis revealed the nature of the API and the fact that it was still 
a mixture of unknown compounds which need separation for complete elucidation. 
Chromatographic techniques used in this study were employed to separate and 
isolate compounds in the API. Eight compounds were successfully isolated. During 
the phytochemical screening, four classes of compounds (flavonoids, alkaloids, fatty 
acids and sugars) were identified by the use of chemical spraying reagents (vanillin, 
iodine vapor, ammonia and nihydrin sprays). Only two compounds were successfully 
structurally elucidated and these were identified as rosmarinic acid and bornesitol. 
Rosmarinic acid showed weak anti-HIV activity (IC50 of 111 µg/ml) while bornesitol 
exhibited no activity.  
Both compounds are well known, but have never been isolated from L trigonus. RA 
is known for its biological activities including anti-viral and anti-oxidant properties. 
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The other six (three alkaloids and three polyphenols) compounds also showed very 
weak to moderate anti-HIV activity and it appears that API activity is dependent on a 
combination of these components. This is reflected in Table 4. 
The API has been identified as a galacturonic acid-rich polymer with other small 
molecules attached to it. The plant oven drying and grinding process was shown to 
contribute significantly to the formation of this polymer. The API production method 
was optimised and refined with the energy intensive spray drying process being 
eliminated. 
As the main contribution of the present study was towards development of a 
microbicide to help protect and improve the lives of women against sexual 
transmission of HIV, it was, therefore, concluded that the precipitated mixture (BP36-
117-26464C) of compounds was the best API, in terms of activity, for further 
development as the microbicide, particularly as it was water soluble. 
Characterisation of the API, including its decolourisation, was important as the main 
problem of the API was the dark colour that needed to be removed while at the same 
time maintaining the anti-HIV activity of the compound. Different decolourisation 
techniques were employed to improve the chances of using the API in a microbicide 
gel. Polyvinylpolypyrrolidone (PVPP) was found to be the best decolourising agent to 
remove the colour of the API and also retain its activity. For the intra-vaginal caplet 
formulations, there was no need to decolourise the API.  
The University of Witwatersrand, Johannesburg, South Africa and MSM, Pretoria, 
were two collaborators responsible for the formulation of the API as described in 
chapter 5. A large scale batch (57 g) was prepared for the two groups to undertake 
these studies. Before the final product (API) can reach the market, a series of 
biological assays are still outstanding. For instance, the vaginal studies are still 
underway where a pig model is being used to test for the irritancy and stability of the 
caplet.  
Besides the dark colour of the API posing a deterrent for further development, there 
was also the issue of compliance with a gel microbicide formulation. Hence, it was 
decided to prepare the gel for demonstration purposes only and not to pursue with 
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the irritancy studies on this formulation and to rather focus on an alternative 
formulation i.e. the caplet which has better chance of clinical success. 
In the current form, the precipitate (API) would be difficult to develop as an oral 
treatment for HIV, as high-molecular weight agents often have poor bioavailability 
following oral administration. However, large molecules with potent anti-HIV activity 
are ideal for topical use and potent development as a microbicide. Unlike the other 
carbohydrate microbicides which have poor anti-HIV properties, the API has been 
shown to have significant anti-HIV activity (Table 4). 
The API was also screened against 10 sub type C clinical isolates and showed anti-
HIV activity against most of these isolates. A target based time of addition assay 
(which shows the trend in which the active shows a reduced ability to block infection 
when added at different time points after completion of each stage of the viral life) 
showed that the API acts in the early stages of HIV as an entry (attachment) 
inhibitor, substantiating its use as a topical microbicide. The advantage of having an 
entry inhibitor is that it could help prevent infection of cells altogether whereas the 
classical interventions such as the Reverse Transcriptase inhibitors act only after 
infection. 
Other ongoing studies involve determining a more detailed toxicity profile of the API, 
confirmatory screening of the API in a PBMC assay against clinically relevant strains 
of the virus and evaluation of the API for efficacy against other STIs.  
 
6.1 Challenges during the study 
Isolation of active phyto-pharmaceutical ingredients, which was one of the main 
objectives of the study, was challenging as the techniques employed were restricted 
to small scale. This proved a disadvantage because bioassay-guided fractionation 
requires a stepwise isolation of active compounds.  
Having discovered a means of purification through re-extraction of the API using 
different solvents, the yields recovered were too low - hence the acetone-water, 
MeOH extracts could not be purified further even though the activity was significant. 
The concentration of the compounds of interest was relatively low. 
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After the API was identified, its characterization was extremely difficult, because it 
was a complex polymer with unknown small molecules attached to or embedded in 
it. It, therefore, needed specialized techniques more suited to polymeric molecules 
and time was spent in trying to find a suitable chromatographic technique that can 
purify and separate the active compounds. The only technique which proved 
successful could only separate the small molecules (polyphenols, alkaloids and 
sugars). The concentration of sugars and how they were arranged, structured and 
holding up together in the API could not be determined as well. Therefore, more 
efficient purification methods are required to isolate and characterize the large 
molecules in the API of L. trigonus. 
As the study was of great importance in developing and identifying an API for use in 
a microbicide, the API had to be decolourised for the purpose of gel formulation. 
Time was invested in trying to find the right decolourising agent that would remove 
the colour of the API and yet retain the anti-HIV activity. PVPP, which was identified 
as the best polymer for decolourisation was very expensive, and could not be used 
for larger scale purifications.  
Due to the complexity of the compounds, structural elucidation of the other six 
compounds could not be achieved and, hence, the structure of only two compounds 
is reported in the present study. Therefore, more investigation needs to be 
conducted on this plant in order to identify other small molecules as well as the 
polymeric molecule/s. The individual compounds will need to be tested for anti-HIV 
activity but all evidence to date indicates that the API is a mixture of molecules of 
various sizes which act together to produce anti-HIV activity.  
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CHAPTER 7: GENERAL MATERIALS AND METHODS 
7. Experimental  
7.1 Extract preparation 
L. trigonus was initially brought to the CSIR by a traditional healer for HIV treatment. 
The plant was collected from Grahamstown, in the Eastern Cape region of South 
Africa. The aerial plant parts were identified by the South African National 
Biodiversity Institute (SANBI Genspec number: 1492 44). 
The aerial parts of the plant were collected and dried in an oven at 30–60°C for 3 
days. Dried aerial parts were ground to a coarse powder using a hammer mill and 
stored at 4°C prior to the extractions. The extraction procedure was carried out as 
per the traditional method of preparation. Distilled cold water was added to the 
ground extract, consistently boiled for 30 minutes and allowed to cool at 4°C for 
about 3 hours before filtering. For the scaling up production of the extract this 
procedure was repeated several times. The aqueous extract was concentrated by 
freeze drying for 3 days. 
For the preparation of the precipitate (API), the aqueous freeze-dried extract was re-
suspended in distilled water. The suspension was cooled at 4°C and mixed with 96% 
ethanol (EtOH). Immediately after the ethanol addition, a precipitate was observed. 
The precipitate was recovered through centrifugation (for 25 minutes at 5000 x g at 
4°C). Both the filtrate (supernatant) and the precipitate (API) were freeze dried. The 
dried filtrate and the precipitate were stored at 4°C until use. 
Three major extracts of L. trigonus were analysed and screened: 
 Lob-1-13A – a spray dried extract prepared by water extraction via spray 
drying process. It showed significant anti-HIV activity. 
 BP36-117-26464C (API) – a precipitate which was identified as the API was 
derived from the spray dried extract through the ethanol precipitation process 
described above. This was the most active API amongst others. 
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 BP36-117-26454B – a filtrate which was the supernatant during the ethanol 
precipitation. It also showed moderate activity against HIV-1 
 
7.2 Chemical reagents 
Analytical grade solvents for extraction and HPLC grade solvents for 
chromatography were purchased from Sigma-Aldrich and Merck. Formic acid (98.0–
100.0%) was purchased also from Sigma Aldrich (South Africa). Reference materials 
rosmarinic acid (>98.0% purity), galacturonic acid, poly-galacturonic acid, pectin from 
citrus and pectin from an apple peel, xylose, Mannose, galactose, glucose and 
Arabinose (>98.0% HPLC purity) were purchased from Sigma Aldrich (South Africa). 
DEAE cellulose (Cellex-d), sephadex G 25 and silica gel 60 were purchased from 
Sigma Aldrich. Distilled water (H2O) was used for all procedures. Finally, for the 
decolourisation of the API, activated charcoal, PVPP, MgSO4 and dialysis 
membranes (10 000 and 12 500 MW) were all procured from Sigma.  
 
7.3 Chromatography 
7.3.1 Liquid-liquid partitioning 
A standard liquid-liquid (L/L) partitioning process was performed on the spray dried 
aqueous extract (Lob-1-13A) and the precipitate- API BP36-117-26464C using 
various solvents. Both the extract and the precipitate (2 g) were dissolved into 
distilled water (50 ml) and re-extracted with the following solvents: 
 Methanol / ethyl acetate / acetic acid (100:60:10) 
 Butanol / ethyl acetate / acetic acid (100:60:10) 
 Acetone / dH2O (140: 60) 
The organic layers were separated, evaporated individually under reduced pressure. 
These layers were purified, screened for HIV activity and ultimately chemically 
analyzed. 
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Extracts produced were:  
 BP36-117-264504 Methanol extract 
 BP36-117-264504 BuOH extract 
 BP36-117-264504 Acet/H2O extract 
 
7.3.2 Preparative thin layer chromatography 
Preparative thin layer chromatography (prep TLC) and thin layer chromatography 
(TLC) were tools used to purify and separate compounds. Pool of fractions was 
purified by this technique. TLC Silica gel 60 F254 plates were purchased from 
Merck. Crude extracts and pure compounds were dissolved in methanol (AR grade), 
spotted and developed on a TLC plate with Chloroform (7): methanol (3): acetic acid 
(2) solvent systems. Before heating the plates in an oven at 80°C, the plates were 
first viewed under UV lamp, sprayed with four spraying reagents i.e. Ammonia and 
Iodine vapour for the detection of the polyphenolic compounds, vanillin: concentrated 
H2SO4 (1 g: 100 ml) for the general compounds like fatty acids and lastly ninhydrin 
(0.2g ninhydrin in 100 ml ethanol and heated to 110°C until spots appear) / Nitric 
acid: ethanol (50 drops conc. nitric acid in 100 ml ethanol. If necessary, heat to 
120°C for the detection of the alkaloids and amines.  
 
7.3.3 Gas chromatography (Silylation process) 
The process of methanolysis and derivatisation was carried out as follows:- 
Step 1: prepare a concentration of 20 mg/ml for every monosaccharide and the API 
Step 2: take 5 µl from each (from the concentration in step 1) monosaccharide, add 
80 µl of mannitol (standard) and combine them in one vial 
Step 3: take 10 µl, 15 µl, 20 µl, 40 µl, 60 µl and 80 µl as described in step 2 
Step 4: completely dry each in a Speedy Vac evaporator 
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Step 5 (methanolysis): add 400 µl of 4M MeOH/HCl in each, close the vials and 
heat the samples in the oven at 60°C for 24 hours  
Step 6: add 500 µl of MeOH at least 4 times in each vial, let it evaporate under fume 
hood to a minimum volume of 20 µl 
Step 7: removal of excess HCl by blowing N2 gas into each vial until no smell 
Step 8 (silylation): In anhydrous pyridine (2 ml), a mixture of HMDS (800 µl) and 
TMCS (400 µl) were combined and mixed well. 200 µl of the mixture was added to 
the hydrolysed and methanolysed 21 samples (sugars, polymers and the API). This 
reaction was held for 30 min at 60°C. The samples were centrifuged to remove the 
excess silica and then transferred to the GC glass vials with inserts. The derivatized 
monosaccharides were injected directly as a pyridine solution and analysed. This 
was done in triplicate so as to check for inconsistencies and to check if the reactions 
were complete as the silylation was very humid-sensitive.  
 
7.3.4 Semi preparative HPLC 
The active extract (BP36-117-264501-Acet/H2O) generated from the PVPP crude 
extract was fractionated using the Agilent 1200 semi-preparative HPLC system 
consisting of an auto sampler, high pressure mixing pump, column oven and DAD 
detector. Sample concentration was 20 mg/ml in DMSO. Semi pure fractions which 
mainly contained flavonoids were evaporated on a GeneVac EZ-2 Plus evaporator at 
40ºC using the pre-installed HPLC fractions vacuum settings. The fractions were 
then spotted on the TLC for the profile and NMR analysed. 
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7.3.4.1 Method parameters 
Column:   Waters SunFireTM Prep C18 
Column temperature: 45˚C 
Flow rate:   4mL/min 
Injection volume:  500 µL 
Detector:   PDA (Photo diode array)  
    Scanned wavelengths from 210 – 600 nm 
Solvents:   A = 0.1 % Formic acid in ddH2O 
    B = Acetonitrile   
 
Table 9: Solvent gradient 
Time 
(min) 
% Solvent A 
0.1 %FA in 
ddH2O 
% Solvent B 
Acetonitrile 
Flow rate 
(mL/min) 
0 0 5 4 
30 0 100 4 
35 0 100 4 
36 0 5 4 
40 0 5 4 
 
7.4 Nuclear magnetic resonance (NMR) spectroscopy 
NMR data was acquired on several fractions and pure compounds including the API. 
The NMR used was a 600 MHz Varian, 5 mm probe. Structural characterization was 
carried out using a combination of 1D (1H, 13C) and various 2D Distortionless 
enhancement by polarisation transfer, Correlation spectroscopy, Heteronuclear 
single quantum coherence and Heteronuclear multiple bond correlation experiments. 
Structural elucidation of other compounds could not be determined due to their 
complexity. The concentration of the samples was 20 mg in 400 µl of the deuterated 
methanol (CD3OD) water (D2O) and chloroform (CD3Cl). 
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7.5 HIV -1 Neutralisation assay protocol 
7.5.1 Reagents 
• Media: DMEM5  
• Pseudovirus diluted according to titration experiments to give a concentration 
of 100 TCID50 
• HIV-1 subtype A, B and C pseudovirions screened 
• Cells: TZM-bl cells (2x105 cells/ml), 10 000 cells/well 
• Compounds to be tested: all the pure compounds or active-rich fractions from 
Lobostemon trigonus including the API 
• Bright Glo luciferase substrate solution (Promega) 
7.5.2 Positive controls 
• T20 (Entry/Fusion inhibitor) 
• Tenofovir (Reverse transcriptase inhibitor) 
7.5.3 Procedure 
 Add 60 µl DMEM5 to all wells, add an extra 25 µl to cell control (CC) wells 
 Add 15 µl compound (1 mg/ml) to bottom row wells in duplicate 
 Prepare a serial 5-fold dilution in 15 µl of the compound by transferring  15 µl of 
the media to upper wells before discarding 15µl from the top row wells 
 Add 25 µl virus (100 TCID50) to all wells, except CC 
 Add 50 µl TZM-bl cells (2x105 cells/ml) to all wells 
 Incubate 48 hrs, 37°C, 5%CO2 
 Remove and discard 75 µl from all wells 
 Add 50 µl Bright Glo luciferase substrate (Promega) to all wells 
 Incubate 2 min 
 Transfer 50 µl of media from all wells to a black, flat bottom NUNC plate 
 Read luminescence with a luminometer 
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 Analyse results in Excel 
 
7.6 Antiviral assay method 
To test the potency of these compounds against herpes simplex virus 2 (HSV-2), 
Vero cells were seeded at 0.5x106 cells/well in 24 well plate for 24 hours to obtain 
80-90% monolayer confluence. Thereafter, the media was removed and the 
monolayer washed three times with PBS prior to virus adsorption. Virus at a 
multiplicity of infection (m.o.i) of 0.05 particle forming unit (p.f.u) was allowed to 
adsorb for 1 hour. At the end of adsorption, traces of virus were removed. Cell 
monolayer was then treated with 500 ug/ml or 100 ug/ml of compounds in DMSO.  
 
A drug that is currently used to treat symptomatic herpes simplex virus, acyclovir, 
was used as a positive control at 5 ug/ml (Whitley 1993). The plate was then 
incubated for 5 days to allow virus-cytopathic effects formation. Cytopathic effect 
was measured by using a 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay kit (Promega Corporation 
(Madison, United State of America) according to the manufacturer’s instructions.  
 
The compound tetrazolium, is converted into a blue formazan dye by metabolically 
active mitochondria of viable cells (Mosmann 1983). At the end of the incubation 
period, cells were incubated with MTS solution for a minimum of 2 hrs, and the 
absorbance was measured at 492 nm using a spectrophotometric microtitre plate 
reader (Infinite, F500, Tecan group Ltd, Mannedorf, Switzerland). 
The percentage of CPE inhibition was calculated by subtracting the mean value of 
virus-infected cell control (0%) from the measured absorbance, and resulting 
number was divided by the measured absorbance of uninfected cell control (100%) 
using equation (2) below: 
CPE inhibition (%) = 100* [(ODcmp- ODvc/ODcmp)/ ODcc](2) 
Where, ODcmp is the optical density of the test compound, ODvc of the virus control 
and ODcc of cell control (untreated). 
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APPENDIX LIST OF SPECTRA 
 
Spectrum 1: 1H (Proton NMR) of Rosmarinic acid in CD3OD (fig 12) 
 
 
Spectrum 2: 13 C (Carbon NMR) of Rosmarinic acid (RA) in CD3OD 
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Spectrum 3: Proton NMR (1H NMR) of BP36-117-264503-2 in CD3OD (fig 12) 
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Spectrum 4: 13C NMR of BP36-117-264503-2 
 
 
Spectrum 5: 1H NMR of BP36-117-26504-A (acetylated bornesitol – (fig 11) in 
CD3Cl 
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Spectrum 6: 1H NMR of BP36-117-26504-C (bornesitol – fig 14) in D2O 
 
 
Spectrum 7: 13C NMR of BP36-117-26504-C (bornesitol– fig 14) in D2O 
 
 
 
 
 
 
